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ABSTRACT 
 
 
BACKGROUND 
 
Human rhinoviruses (HRV) are the most frequent causative agents of the common cold and are 
also associated with such complications as acute otitis media (AOM) in children and acute 
community-acquired sinusitis (ACAS) in adults. Understanding of the clinical consequences of 
HRV infections is mainly dependent on the development of new detection assays, as the 
insensitivity of the conventional virus isolation method is now well known. The large number 
of HRV serotypes (at least 100) has hampered studies on individual HRV strains because 
serotyping of HRV field strains is virtually impossible in routine clinical diagnosis. 
 
MATERIALS AND METHODS 
 
A cohort of 329 children was followed from the age of two months to two years (FinOM 
Cohort Study). Nasopharyngeal aspirates (NPA) were collected every time the child had an 
upper respiratory infection or AOM. In the case of AOM, middle ear fluid (MEF) and paired 
sera were also obtained. In addition, four scheduled sera were collected from each child. The 
presence of HRV or HRV RNA in the NPA and MEF specimens was studied by virus isolation 
and RT-PCR hybridization. The antibodies to a mixture of HRV serotypes were determined by 
a complement fixation assay. A genomic region encoding the capsid protein VP4 and the N-
terminus of VP2 was sequenced from all assigned HRV prototype strains, and the obtained 
sequences were subjected to phylogenetic analysis.  
 
RESULTS  
 
A rapid and sensitive microwell RT-PCR hybridization assay for detection of HRV RNA was 
developed and shown to be especially useful in the analysis of large numbers of clinical 
specimens. HRV infections were demonstrated to be very common in a cohort of young 
children. By the age of two years, 80% of children had experienced a virologically documented 
HRV infection, and more than 90% had HRV-specific antibodies. HRV was detected in 41% of 
AOM episodes. According to the phylogenetic analysis of HRV prototype and field strains, 
rhinoviruses clustered into two distinct genetic groups, HRV-A and HRV-B. One of the HRV 
serotypes, HRV87, was shown to previously be incorrectly assigned as a rhinovirus. It 
represents the same serotype as EV68 and belongs to enterovirus species HEV-D together with 
EV70. In contrast to other enteroviruses, HRV87 and EV68 are sensitive to low pH.  
 
CONCLUSIONS 
 
Rhinoviruses were shown to be very common in young children, and the close association 
between HRV infections and AOM was confirmed. Molecular-based methods (RT-PCR and 
sequencing) can be recommended as the primary tools for both diagnosis of HRV infections 
and characterization of HRV field strains. The acid sensitivity of HRV87 and EV68 indicates 
that the traditional classification of rhinoviruses and enteroviruses according to biological 
properties alone may be misleading. 
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1 INTRODUCTION 
 
 
 
Acute upper respiratory infections, generally known as common colds, are the most 
frequent acute illnesses world-wide. The predominant role of human rhinoviruses 
(HRV) in the aetiology of the common cold was already established in the studies 
conducted in the 1960s, when only virus isolation techniques were in use. However, the 
lack of means for treating of rhinovirus infections and laborious diagnostic procedures 
have hindered progress in the studies on rhinovirus infections for some decades. 
 
Recently, rapid and sensitive molecular-based RT-PCR methods have replaced  
conventional virus isolation in rhinovirus diagnostics. Rhinovirus infections are 
estimated to account for approximately 50% of common colds in adults annually 
(Mäkelä et al., 1998) and 90% or more during the highest prevalence in autumn (Arruda 
et al.,1997; Mäkelä et al., 1998). More importantly, the exploitation of PCR is 
continuously increasing evidence of the association of rhinoviruses with more severe 
diseases such as acute otitis media (AOM), acute community-acquired sinusitis 
(ACAS), wheezing and exacerbations of asthma and chronic obstructive pulmonary 
disease. Improved understanding of the role of rhinoviruses in pathogenesis of these 
diseases, especially in AOM and ACAS, is anticipated to reduce unnecessary antibiotic 
use. With the ongoing development of anti-rhinoviral drugs, attention should now be 
directed towards evaluating both the laboratory methods for rapid and accurate 
rhinovirus diagnoses, and the clinical consequences of rhinovirus infections. 
 
While our knowledge of the frequency and clinical importance of rhinovirus infections 
is growing rapidly, we continue to know little about individual circulating rhinovirus 
strains, which may have differences in, for example, pathogenicity. Elegant molecular 
methods have been applied in epidemiological studies of human enterovirus strains for 
many years, but molecular epidemiological studies on circulating rhinoviruses are still in 
the initial stages. 
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2 REVIEW OF THE LITERATURE 
 
 
2.1 PICORNAVIRUSES  
 
The family Picornaviridae consists of small, non-enveloped RNA viruses and includes 
many common human and animal pathogens, e.g. polio, hepatitis A and food-and-mouth 
disease viruses. According to the most recent virus taxonomic proposal, the family 
contains nine genera (Table 1), with rhinoviruses and enteroviruses being the largest  
(Stanway et al., 2004). Each genus contains one or more species, and each species one 
or more antigenically distinct serotypes. Altogether, the family Picornaviridae contains 
over 200 different serotypes. The taxonomy of Picornaviridae is changing. New 
tentative species have been proposed in three genera (enterovirus, rhinovirus and 
hepatovirus), and over 20 viruses are waiting for assignment in the family.  
 
 
 
Table 1.  Taxonomic structure of the family Picornaviridae. 
 
 
 
Genus   Species    Number of serotypes  
 
Enterovirus  Bovine enterovirus    2 
Human enterovirus A    13 
   Human enterovirus B    41 
   Human enterovirus C    9 
   Human enterovirus D    2 
   Poliovirus     3 
   Porcine enterovirus A    1 
   Porcine enterovirus B    2 
   Simian enterovirus A    2 
Rhinovirus  Human rhinovirus A    75   
   Human rhinovirus B    25 
Cardiovirus  Encephalomyocarditis virus   4   
   Theilovirus     3 
Aphthovirus  Equine rhinitis A virus    1 
Foot-and-mouth disease virus   7   
Hepatovirus  Hepatitis A virus    2  
Parechovirus  Human parechovirus    3   
   Ljungan virus     1 
Erbovirus  Equine rhinitis B virus    2    
Kobuvirus  Aichi virus     1 
   Bovine kobuvirus   1    
Teschovirus  Porcine teschovirus    11    
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2.2 HUMAN RHINOVIRUSES  
 
 
2.2.1 EARLY HISTORY OF RHINOVIRUS RESEARCH 
   
The first successful in vitro isolation of rhinovirus was carried out by serially passaging 
the virus in human lung explants. This DC strain, later HRV9, was isolated in 1953 
from a nasal washing of a cell biologist who worked at the Common Cold Research 
Unit, England, and had symptoms of upper respiratory infection (Andrewes et al., 1953; 
Tyrrell & Fielder, 2002). Some years later, cytopathogenic agents were isolated from 
nasopharyngeal washings in rhesus monkey kidney tissue cultures in two laboratories in 
the United States (Price, 1956; Pelon et al., 1957). These two strains, JH and 2060, were 
shown to be serologically identical and were named Echo 28 (later HRV1A) because of 
the properties they shared with enteroviruses. The breakthrough in rhinovirus isolations 
occurred in the early 1960s. Tyrrell and Parsons (1960) isolated strain HGP (later 
HRV2) in cultures of human embryonic kidney cells by imitating the conditions of the 
nose. They lowered the incubation temperature to 33C and the pH of the tissue culture 
medium to around 7.0, slowly rotating the cultures during the incubation. At the same 
time, new, sensitive, semicontinuous strains of diploid human embryonic lung 
fibroblasts (e.g. WI-26) were developed (Hayflick & Moorehead, 1961). The 
“conditions of the nose” and new cell lines led to an explosive increase in isolation of 
new strains, many of which were found to be antigenically distinct (Taylor-Robinson & 
Tyrrell, 1962). 
 
Laboratories assigned the new common cold-related viruses in various ways; the names 
Salisbury strain, murivirus, respirovirus, rhinovirus, coryzavirus and ERC (ECHO-
rhino-coryzavirus) were in use (Hilleman, 1967). However, the biological relatedness of 
the strains was soon noticed, and the basic properties of the virus group, especially 
lability in an acidic environment, were established. The name “rhinovirus”, suggested by 
Andrewes in 1961 because of the special adaptation of the viruses for growth in nasal 
epithelium, was chosen as the name for the entire virus group (Tyrrell & Chanock, 
1963). 
 
 
 
2.2.2 ASSIGNMENT OF RHINOVIRUS PROTOTYPE STRAINS 
 
The rapid identification of new rhinovirus serotypes in the early 1960s made comparison 
of epidemiological data from different laboratories difficult. The National Institute of 
Allergy and Infectious Diseases (NIAID) and the World Health Organization (WHO) 
initiated a Rhinovirus Collaborative Programme, the aim of which was to compare 
antigenic relationships of rhinovirus strains to achieve an acceptable rhinovirus 
designation scheme. The Children’s Hospital in Columbus, Ohio, functioned as a 
reference laboratory that performed reciprocal neutralization tests with submitted 
candidate rhinoviruses and sera. In addition, each laboratory submitting new virus 
strains was ordered to test their own candidate viruses against all available sera. 
REVIEW OF THE LITERATURE 
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Consequently, each candidate virus was tested against each specific antiserum 
independently in at least two laboratories. 
 
The three phases of the Rhinovirus Collaborative Programme are shown in Table 2. In 
Phase I, 68 candidate viruses and corresponding sera were compared by standard 
neutralization assays in HeLa cells (Conant & Hamparian,1968). Six pairs of viruses 
and three groups of three viruses were found to be serologically identical. Of these, the 
virus strain that had been submitted first to the Programme was assigned a prototype 
strain of a given serotype. In addition, two strains, Echo 28 and B632, were shown to be 
significantly related, but not identical, and B632 was assigned as a subtype of Echo 28. 
These strains were given serotype names HRV1A and HRV1B (Kapikian et al., 1967). 
The second phase with 73 rhinovirus candidate strains was carried out in the late 1960s. 
Thirty-four distinct prototype strains were numbered from HRV56 to HRV89 and the 
results were published in 1971 (Kapikian et al., 1971). In 1973, cross-neutralization 
tests were completed for 25 new candidate viruses (Phase III). A  lack of financial 
support prevented completion of the third phase, and the results were only published in 
1987 (Hamparian et al., 1987). In Phase III, 11 new prototype strains were accepted, and 
the numbering was extended to 100. During this stage all available epidemiological data 
were interpreted so that rhinoviruses identified earlier were still circulating and new 
serotypes were not constantly emerging.  
 
During the three-phase NIAID and WHO co-ordinated Rhinovirus Collaborative 
Programme, which continued for eight years, 166 submitted rhinovirus candidate strains 
were tested and 100 rhinovirus serotypes (and one subtype) were assigned a number and 
a prototype strain.  Since the third phase of the Collaborative Programme, only one 
strain, Hanks, has been proposed as a new serotype (Gwaltney et al.,1978). In recent 
years, attempts to identify the serotypes of isolated rhinovirus strains have been 
infrequent, and many unrecognized rhinovirus serotypes may still exist.  
 
 
 
Table 2.  Rhinovirus Collaborative Programme for assigning rhinovirus prototype 
strains.  
 
 
Phase  No. of candidate/ Assigned serotypes Reference 
accepted strains 
 
I  68 / 55   HRV1* - HRV55  Kapikian et al. (1967) 
II  73 / 34   HRV56 - HRV89 Kapikian et al. (1971) 
III  25 / 11   HRV90 - HRV100 Hamparian et al. (1987) 
 
*HRV1 has two subtypes, HRV1A and HRV1B. 
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2.2.3 GENERAL CHARACTERISTICS OF RHINOVIRUSES 
 
 
Rhinoviruses share the basic properties of viruses in the family Picornaviridae. All 
picornaviruses are small (about 30 nm) and spherical in shape, and are composed of an 
icosahedral protein capsid enclosing a single strand of positive-sense RNA. From a  
phylogenetic view, the closest relatives of rhinoviruses are human enteroviruses (HEV), 
but these two viruses differ, for example, with regard to behaviour in an acidic 
environment. Rhinoviruses withstand pH values ranging from 6.0 to 8.0 but are readily 
inactivated below a pH of 6.0. Infectivity of human rhinovirus 14 (HRV14) is reduced at 
pH 5.0 in 20 minutes, and is totally lost at pH 3.0 in 10 seconds. The inactivation of 
HRV14 at pH 5.0 is dependent on temperature; a nearly 99% loss in infectivity occurs 
almost immediately at 24°C, but not in 5 minutes at 0°C (Hughes et al., 1973). In 
contrast to rhinoviruses, enteroviruses are stabile at low pH, but the molecular basis of 
the difference in acid sensitivity between rhino- and enteroviruses is not known. 
Acidification of HRV14 is shown to induce irreversible conformational changes both at 
the surface of the virus and on the capsid interior (Giranda et al., 1992). However, the 
acid sensitivity of rhinoviruses may be altered since acid-resistant mutants of HRV14 
have been obtained by serial exposure of the viruses to pH 4.5 followed by passaging in 
HeLa cells (Skern et al., 1991).    
 
Due to the lack of a lipid envelope, rhinoviruses are resistant to ether, chloroform, 
fluorocarbon and detergents. Proteolytic enzymes, like trypsin, destroy the infectivity of 
some, but not all, of the serotypes (Stott & Killington, 1972). The infectivity of 
rhinoviruses is maintained at 24-37°C, and thus, they can survive on environmental 
surfaces, such as door handles and coffee cups, for hours to days (Hendley et al., 1973). 
Most rhinoviruses are also stabile at higher temperatures (at 50°C), but marked variation 
exists between the different serotypes. At frosty temperatures, rhinoviruses can survive 
for years (Couch, 2001).   
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2.2.4 STRUCTURAL ASPECTS 
 
 
2.2.4.1 STRUCTURE OF RHINOVIRUSES  
 
Detailed atomic structures of five rhinoviruses, HRV1A (Kim et al., 1989), HRV2 
(Verdaguer et al., 2000), HRV3 (Zhao et al., 1996), HRV14 (Rossmann et al., 1985; 
Arnold & Rossmann,  1990) and HRV16 (Oliveira et al., 1993; Hadfield et al., 1997), 
have been determined by X-ray crystallography.  
 
The protein capsid of rhinoviruses is composed of 60 copies of protein subunits, 
protomers, each of which comprise a single molecule of four polypeptides, VP1 to VP4, 
VP1 being the most exposed. Proteins VP1 to VP3 have the same overall structural 
conformation, an eight-stranded antiparallel ß-barrel (Figure 1a), without having any 
remarkable sequence homology. Carboxyl (C) termini of proteins VP1 to VP3 are 
located on the surface of the virion, while amino (N) termini are in the interior. The 
smallest capsid protein VP4 lies on the inner surface of the capsid and is in intimate 
contact with RNA. (Racaniello, 2001). 
 
The capsid of rhinoviruses has icosahedral symmetry (Figure 1b). There is a star-shaped 
plateau at the fivefold axis of symmetry, which is surrounded by a deep cleft or canyon, 
and another protrusion at the threefold axis (Rossmann et al., 1985). The canyon 
separates the major part of five VP1 subunits, clustered about a pentamer axis, from the 
surrounding VP2 and VP3 subunits. Within the core of VP1, just beneath the canyon 
floor, is a hydrophobic tunnel, a “pocket”. (Racaniello, 2001) 
 
The overall folding pattern is well preserved in proteins VP1, VP2 and VP3 in all 
studied rhinoviruses to date. The structural differences between rhinovirus serotypes are 
located mainly on the external surface loops connecting the ß-strands and on the internal 
capsid surfaces, particularly in the conformation of the N-termini of proteins VP4 and 
VP1 (Verdaguer et al., 2000).  The N-termini of VP4 and VP1 together contribute to the 
ß-barrel structure in HRV2, which resembles the structure found in enteroviruses 
(Verdaguer et al., 2000). The N-terminal ends of VP4 and VP1 are disordered in HRV3 
(Zhao et al., 1996) and HRV14 (Rossmann et al., 1985), as is the VP4 N-terminus in 
HRV1A (Kim et al., 1989). The N-terminal amino acids of VP1 proteins form an 
amphipathic helix in HRV1A (Kim et al., 1989) and HRV16 (Hadfield et al., 1997).  
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Figure 1.   
Schematic views of the conformation of the picornavirus capsid protein (a) (Rossmann 
et al., 1985; Racaniello, 2001) and the icosahedral structure of the rhinovirus (b) 
(Rossmann et al., 1985; Racaniello, 2001). The figure is reprinted with the kind 
permission of the publisher. 
a.
b.
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2.2.4.2 ANTIGENIC STRUCTURE AND NEUTRALIZATION MECHANISMS  
 
Neutralizing antigenic epitopes have been located on the surface of two rhinovirus 
serotypes, HRV2 and HRV14, by analysing neutralization-resistant mutants (Table 3). 
All antigenic epitopes were found in hypervariable regions of the capsid proteins at the 
highest points of the virus surface. Four different epitopes were shown to be involved in 
antibody-mediated neutralization of HRV14 (Sherry & Rueckert, 1985; Sherry et al., 
1986). Three of the four epitopes, NImIB, NImII and NImIII, are composed of non-
contiguous sequences located either on the same or on different capsid proteins. NImIA 
and NImIB lie very close to each other (Rossmann et al., 1985). The neutralization of 
HRV2 was shown to involve three antigenic sites, A, B and C. Site A is confined to 
VP1, between the fivefold symmetry axis and the canyon, and closely resembles the 
NImIA site of HRV14. Site B includes residues from all three external capsid proteins. 
The VP2 region of site B is partly analogous to the NImII site of HRV14 (Skern et al., 
1987; Appleyard et al., 1990; Verdaguer et al., 2000).  
 
Several different mechanisms for antibody-driven neutralization of rhinovirus infectivity 
have been suggested, but not universally accepted, as reviewed by (Smith, 2001). These 
mechanisms include aggregation of viruses, stabilization of the viruses leading to 
prevention of uncoating, induction of conformational changes in the capsid, and steric 
blocking of cellular attachment. The major in vitro neutralization mechanism of 
antibodies targeted to all four antigenic sites on HRV14 is proposed to be steric 
blocking of attachment of the virus to cellular receptors (Colonno et al., 1989; Che et 
al., 1998; Smith, 2001). Antibodies to the NImIA site probably also stabilize the virus 
by binding bivalently across the twofold axes in the canyon region, preventing the 
conformational changes needed in the uncoating process (Smith et al., 1993a; Smith et 
al., 1993b; Che et al., 1998).   
 
 
Table 3. Amino acid residues involved in neutralizing antigenic epitopes of HRV2 and                     
HRV14 determined by analysing neutralization-resistant mutants*. 
 
 
VP1    VP2    VP3 
 
HRV2 
Site A  85,86,92 
Site B  260,262,264,265,272,274 159,161,163,164  59,64  
Site C      214,236,238 
 
HRV14 
NImIA  91,95 
NImIB  83,85,138,139 
NImII  210    156,158,159,161,162 
NImIII  287        72,75,78,203 
 
*Table modified from Verdaguer et al. (2000). 
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2.2.4.3 ORGANIZATION AND STRUCTURE OF THE GENOME  
 
The genome of human rhinoviruses is a single-stranded, messenger-sense RNA 
molecule (Figure 2). The complete genomic sequences of five rhinovirus serotypes are 
available in GenBank (HRV1B (Hughes et al., 1988), HRV2 (Skern et al., 1985), 
HRV14 (Stanway et al., 1984), HRV16 (Lee et al., 1995) and HRV89 (Duechler et al., 
1987). In addition, two complete sequences (HRV9 and HRV85) are published on the 
Picornavirus Home Page (Knowles, 1996). The length of the rhinovirus genome is 
7102-7152 bases in HRV1B, HRV2, HRV9, HRV16, HRV85 and HRV89, and 7212 
bases in HRV14.  
 
There are non-coding regions (NCR) at both the 5’ and 3’ ends of the genome. The 5’ 
NCR of the sequenced rhinoviruses is 610-625 bases long, and thus, some 100 bases 
shorter than that in enteroviruses. The 100-base-long insertion in enterovirus 5’ NCR, 
generally known as the hypervariable region, is located just before the protein-coding 
region. The 5’ NCR has conserved sequence and secondary structure stretches, which 
are involved in the initiation of replication and translation (reviewed in (Xiang et al., 
1997)), and are shared by rhino- and enteroviruses (Rivera et al., 1988). A small protein, 
VPg, is covalently attached to the 5’ end of the genome (Lee et al., 1977) with its 
conserved third amino acid, tyrosine. VPg is encoded by a single viral gene (3B), and its 
length varies in rhinoviruses from 21 (HRV1B, HRV2, HRV9, HRV16, HRV85 and 
HRV89) to 23 (HRV14) amino acids. The 3’ NCR is 40-47 bases long, which is much 
shorter than the 70-120 bases found in enteroviruses. The genome ends with a stretch of 
poly(A). 
 
Residing between the 5’ and 3’ non-coding regions is a single open reading frame 
(ORF) that encodes a polyprotein 2100-2200 amino acids long. The polyprotein is 
translated as a precursor, which is further processed into individual structural and non-
structural proteins. The P1 region encodes the four capsid proteins VP4, VP2, VP3 and 
VP1. The P2 and P3 regions encode seven proteins involved in protein processing and 
genome replication. (Racaniello, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.   Schematic view of the organization of the rhinovirus genome. 
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2.2.5 LIFE CYCLE OF RHINOVIRUSES 
 
Replication of human rhinoviruses takes place in the cytoplasm of the host cell. The first 
step in rhinovirus life cycle is attachment to a cell surface receptor, which is either 
intercellular adhesion molecule 1 (ICAM-1) (major receptor group) (Greve et al., 1989; 
Staunton et al., 1989; Tomassini et al., 1989) or a member of the low-density 
lipoprotein (LDL) receptor family (minor receptor group) (Hofer et al., 1994; 
Gruenberger et al., 1995; Marlovits et al., 1998). ICAM-1 is a cell surface member of 
the immunoglobulin supergene family. The binding site of ICAM-1 has been located at 
the base of the canyon by cryoelectron microscopy and image reconstruction analysis of 
receptor-bound structures of HRV3 (Xing et al., 2003), HRV14 (Kolatkar et al., 1999) 
and HRV16 (Olson et al., 1993). The LDL receptor family consists of cell surface 
receptors, such as the LDL receptor, the very low-density lipoprotein (VLDL) receptor 
and the LDL receptor-related protein, which mediate the transport of lipoproteins into 
cells by receptor-mediated endocytosis. They are proposed to bind their ligands by 
electrostatic interactions with negatively charged ligand-binding domains. The VLDL 
receptor footprint in HRV2 is on the star-shaped dome of the icosahedral fivefold axis 
formed by the BC and HI loops of VP1 (Hewat et al., 2000).  
 
The attachment of the virus to the cellular receptor triggers conformational changes in 
the virus capsid, eventually leading to a release of viral RNA into the cytoplasm. This 
uncoating process is proposed to occur by different mechanisms in major and minor 
receptor group viruses. Binding of ICAM-1 to HRV14 initiates a rapid uncoating 
without a need for any cellular machinery (Greve et al., 1991; Casasnovas & Springer, 
1994), whereas the release of HRV2 RNA into the cytoplasm is mediated by clathrin-
dependent internalization of the virus into acidic endosomal compartments (Neubauer et 
al., 1987; Prchla et al., 1994; Schober et al., 1998; Snyers et al., 2003).  
 
In the cell cytoplasm, the viral genome is translated to provide viral proteins essential 
for genome replication and the production of new virus particles. The long polyprotein 
precursor first cleaves itself into the intermediates P1, P2 and P3 via two proteinases, 
2A and 3C/3CD. P1 is then further cleaved to yield VP0, VP1 and VP3. VP0 is cleaved 
to VP4 and VP2 during viral assembly. Among other proteins synthesized are the viral 
RNA-dependent RNA polymerase and accessory proteins required for genome 
replication and mRNA synthesis. The positive-stranded RNA is copied to a negative-
stranded intermediate, an RNA molecule with a complementary nucleotide sequence. 
Synthesis of the complementary (-) strain is initiated at the 3’ terminus of the RNA and 
primed by the protein VPg. This complementary (-) strain is subsequently used as a 
template in synthesizing large numbers of copies of the viral genome, which are used as 
mRNA for translation of more viral proteins or, later in the infection cycle, packaged 
into new virus particles. The new infectious viruses are assembled in the cytoplasm and 
finally released from the cell. (Racaniello, 2001). 
 
The time course of the replication cycle of rhinoviruses is similar in cell cultures and 
experimental infections in humans. In one-cycle in vitro growth experiments, a newly 
produced virus could frequently be detected in 5-7 hours, and the cycle of viral 
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replication was complete in 10-12 hours. However, depending on the cell line and 
serotype of the virus, the first appearance may be as late as 9 hours, with completion in 
15-17 hours (Stott & Killington, 1972). In HRV39-challenged adult volunteers, the new 
virus was recovered in nasal washings 11.3 (range 8 -18) hours after inoculation. The 
virus titres remained almost stabile until 18 hours after challenge, then increasing again 
as a consequence of a second cycle of viral replication. The highest titres were reached 
48 hours after virus challenge; titres began to decline on day 3 and remained low on 
days 4 and 5 (Harris & Gwaltney, 1996; Hendley & Gwaltney, 2004).  
 
 
 
2.2.6 SUBGROUPS OF RHINOVIRUSES 
 
 
The genus Rhinovirus contains a considerably large number of viruses, over 100 
antigenically distinguishable types. Although the rhinoviruses share many common 
properties, such as overall structure and acid sensitivity, they do not comprise a fully 
homogeneous virus group, differing from each other in many important aspects, 
including growth properties in cell cultures, receptor usage and antiviral sensitivities. 
These differences, together with antigenic and phylogenetic relationships, have been 
exploited in classifying the rhinoviruses into subgroups. 
 
 
2.2.6.1 GROWTH PROPERTIES IN CELL CULTURES  
 
The first rhinovirus strains isolated from clinical specimens were classified as H or M 
strains according to their growth properties in different cell lines (Taylor-Robinson & 
Tyrrell, 1962; Hilleman, 1967). H strains grew only in human embryonic kidney cells, 
while M strains grew in both human and monkey kidney cells. Allocation of 
rhinoviruses into M or H strains has subsequently been shown to be of limited 
importance. Some of the H strains were adapted to grow in monkey cells (Douglas et 
al., 1966), and both M and H strains were isolated from rhinoviruses HRV15, HRV33 
(Phillips et al., 1965) and HRV39 (Mufson et al., 1965). Most of the rhinovirus 
serotypes (at least HRV1A, HRV1B, HRV2, HRV29, HRV30, HRV31, HRV47 and 
HRV62) originally classified as M strains (Hilleman, 1967) belong to the minor receptor 
group of rhinoviruses.  
 
 
2.2.6.2 RECEPTOR USAGE 
 
Classification of rhinoviruses into either the major or minor receptor group was initiated 
before the receptors were known by pair-wise competition binding assays in HeLa R-19 
cells (Abraham & Colonno, 1984), and after ICAM-1 was identified as a major receptor, 
the classification was completed with HeLa cell protection assays with monoclonal 
antibody to ICAM-1 (Uncapher et al., 1991). According to these results, the major 
receptor group consists of 91 serotypes (including the unnumbered strain Hanks) and the 
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minor receptor group of 10 serotypes, HRV1A, HRV1B, HRV2, HRV29, HRV30, 
HRV31, HRV44, HRV47, HRV49 and HRV62 (Uncapher et al., 1991). HRV87 was the 
only serotype that could not be classified into either of these groups. Unlike other 
rhinoviruses, its attachment to HeLa cells was inhibited by pre-treatment with 
neuraminidase, and thus, its receptor was suggested to be a sialoprotein (Uncapher et al., 
991). The existence of two receptor groups was further confirmed by analysing the 
inhibitory activities of soluble ICAM-1 molecules. Soluble ICAM-1 inhibited the 
replication of all assigned major receptor group rhinoviruses, except HRV23 and 
HRV25, but did not affect the replication of minor receptor group rhinoviruses or 
HRV87 (Crump et al., 1993). 
 
 
2.2.6.3 ANTIVIRAL SENSITIVITY  
 
A variety of structurally unrelated antiviral compounds are capable of inhibiting the 
replication of rhinoviruses. All of these compounds share the same binding site, a 
hydrophobic pocket in capsid protein VP1, but have a different effect on distinct viruses. 
A systematic, multivariate analysis of 100 rhinovirus serotypes against a panel of 15 
antiviral compounds divided rhinoviruses into two antiviral groups, A and B. Antiviral 
group A was shown to consist of 33 serotypes with a more than average susceptibility to 
elongated antiviral compounds such as WIN51711. Antiviral group B contains 67 
serotypes that are susceptible to structurally shorter antiviral agents, including chalcone, 
dichloroflavan and R61837 (Andries et al., 1990; Andries et al., 1991). 
 
 
2.2.6.4 ANTIGENIC RELATIONSHIPS  
 
By the original definition of a rhinovirus serotype, a new serotype is approved only after 
it has been shown not to exhibit significant antigenic cross-reactivity with known 
serotypes (Kapikian et al., 1967). However, studies with hyperimmune rabbit and 
guinea pig sera have indicated many cross-reactions between the existing serotypes. 
According to a systematic analysis of antigenic relationships among 90 rhinovirus 
serotypes (HRV1-HRV89), 50 of these serotypes were divided into 16 antigenic groups, 
each of which contains 2-10 antigenically related serotypes (Cooney et al., 1982). 
Reciprocal neutralization was demonstrated for virus pairs HRV1A-HRV1B, HRV2-
HRV49, HRV3-HRV14, HRV9-HRV32, HRV12-HRV78, HRV13-HRV41, HRV15-
HRV74, HRV29-HRV44 and HRV36-HRV58 (Cooney et al., 1973, 1982). Many more 
serotypes have been shown to be related with one-way cross-reactions (HRV5-HRV42, 
HRV6-HRV14, HRV9-HRV67, HRV11-HRV40, HRV11-HRV74, HRV17-HRV42, 
HRV17-HRV70, HRV22-HRV61, HRV32-HRV67, HRV36-HRV50, HRV36-HRV89, 
HRV39-HRV54, HRV40-HRV56, HRV60-HRV38, HRV66-HRV77 and HRV76-
HRV11) (Cooney & Kenny, 1970; Calhoun et al., 1974; Cooney et al., 1982). The 
observed heterotypic responses have usually been of a low order of magnitude, but 
sequential injections of related rhinovirus antigens have been shown to amplify the 
responses; the antigenic groups that include HRV13 and HRV41, and HRV9, HRV32 
and HRV67, were determined this way (Cooney et al., 1975).  
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Heterotypic antibody responses have been demonstrated also in man after natural 
infection. Following natural infection with one of the related serotypes of HRV1A and 
HRV1B, HRV2 and HRV49, HRV23 and HRV30, or HRV29, HRV44 and HRV62, the 
antibody response to the second virus was almost equal to the homotype and was 
suggested to provide cross-protection for infection (Mogabgab et al., 1975). Besides 
multiple antigenic cross-reactions among the different rhinovirus serotypes, marked 
variation is another major feature in the antigenicity of rhinoviruses. Rapid antigenic 
variation has been demonstrated for HRV17 under in vitro immunological pressure 
(Patterson & Hamparian, 1997), and antigenic variants have also been described for 
HRV51 (Stott & Walker, 1969), HRV54 (Hamparian et al., 1987) and HRV91 
(Hamparian et al., 1987). 
 
 
2.2.6.5 PHYLOGENETIC RELATIONSHIPS 
 
Genetically, human rhinoviruses cluster into two distinct groups, HRV-A and HRV-B. 
The existence of different genetic groups was suggested already when the first three 
complete genomic sequences, HRV2, HRV14 and HRV89, were determined, and HRV2 
and HRV89 were found to be much more closely related to each other than to HRV14 
(Duechler et al., 1987). The two groups were specified by Horsnell and colleagues in 
1995 after sequencing a genomic region including the immunogenic site NImII from 12 
more rhinovirus prototypes. In phylogenetic analysis, the viruses were shown to cluster 
into two genetic groups, group 1 containing more serotypes than HRV14-related group 2 
(Horsnell et al., 1995). The same two groups were again observed after analysis of 5’ 
NCR sequences from 39 rhinovirus strains (both prototype and clinical strains) 
(Andeweg et al., 1999).  
 
 
 
2.2.7 RHINOVIRUSES AS INFECTIOUS AGENTS IN HUMANS 
 
2.2.7.1 NATURAL COURSE OF RHINOVIRUS INFECTION  
 
A rhinovirus infection is initiated by delivery of the virus into the front of the nose or 
into the eye, where it passes down the lacrimal duct. A very small amount of the virus 
(as little as one tissue culture infectious dose50) can produce infection when deposited in 
the nose. Introduction of the rhinovirus directly into the mouth or throat does not initiate 
infection efficiently, as reviewed by Gwaltney and Hendley (1978). Rhinoviruses target 
the cells of the nasal epithelium. In some experimental infections, only a small subset of 
epithelial cells in upper airway tissues have been shown to become infected (Winther et 
al., 1986; Bardin et al., 1994; Arruda et al., 1995), but in natural infection, rhinovirus 
RNA has been detected in a high proportion of nasal epithelium cells by a sensitive in 
situ hybridization assay (Pitkäranta et al., 2003). Evidence that lower epithelial cells 
have a similar susceptibility to rhinovirus infection as the upper respiratory epithelium is 
increasing (e.g. (Gern et al., 1997; Papadopoulos et al., 1999; Papadopoulos et al., 
2000; Mosser et al., 2002; Hayden, 2004). The proposed optimal growth temperature of 
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most rhinovirus serotypes (33°C) corresponds to the temperature of the nasal mucosa; 
however, thermal mapping of the airways has indicated that during quiet breathing the 
temperature, at least in the large airways (33-35°C) approaches the optimal temperature 
for rhinoviruses (reviewed by Gern, 2002). In addition, some rhinovirus strains have 
been shown to replicate as well or even better at lower airway temperatures (37°C)  
(Papadopoulos et al., 1999). However, the primary site of replication seems to be the 
nasal mucosa, which is indirectly supported by findings that in natural infections in man 
rhinovirus concentrations are higher in nasal secretions than in pharyngeal secretions, 
saliva or secretions obtained by simulated coughs and sneezes (Hendley et al., 1973). 
Rhinoviruses are believed not to infect the intestine, and attempts to infect the intestinal 
tract of adult volunteers have been unsuccessful (Cate et al., 1967). Attempts to isolate 
rhinoviruses from feces of children hospitalized with diarrheal symptoms have also 
failed, although rhinovirus infection could be proven by isolation of the virus from 
simultaneously collected nose swabs (Stott et al., 1969). While a very rare consequence 
of rhinovirus infection, rhinoviremia has been reported after isolating the virus from 
post-mortem sera of two small children (Urquhart & Stott, 1970). 
 
The predominant illness caused by rhinoviruses is acute upper respiratory infection, 
otherwise known as the common cold. The first symptom is often a sore throat; other 
typical symptoms include sneezing, nasal obstruction and nasal discharge. Hoarseness, 
cough, headache, fever and malaise may also occur (Couch, 2001). The incubation 
period of rhinovirus infection is very short, 8-12 hours in experimental infections 
(Naclerio et al., 1988; Harris & Gwaltney, 1996). The first symptoms occur soon after 
virus entry into the nose and peak on days two to three of infection. The median 
duration of illness is seven days in young adults, but may be up to two weeks in one-
fourth of cases, or even longer in children and in the elderly. Of experimentally 
challenged susceptible volunteers, 95% have become infected, with 75% of infected 
persons developing a cold with typical symptoms. While the amount of virus in nasal 
secretions is small after the first three days of infection, viral shedding in nasal 
secretions may continue for up to three weeks (reviewed by Gwaltney, 2002). After 
onset of a natural rhinovirus infection in children, rhinovirus RNA was detectable in 
nasal secretions for two weeks in half of the cases and could still be detected after five 
weeks in one case (Jartti et al., 2004). 
 
Rhinovirus infection elicits serotype-specific immunity. In experimental HRV15 
infections, neutralizing antibodies could be detected in serum 14-17 days after 
inoculation, and peak titres were reached at 4-5 weeks. Titres are proposed to persist for 
at least 1-3 years (Douglas, 1970). In natural rhinovirus illnesses, neutralizing antibody 
titres in serum rise in 75-80% of persons (Gwaltney et al., 1967; Hendley et al., 1969). 
IgA antibodies are found in nasal secretions in close association with serum IgG and 
IgA antibodies, but the clearance of nasal antibodies seems to be faster than that of 
serum antibodies (Cate et al., 1966). The amount of serum neutralizing antibody has 
been shown to be inversely correlated with the subsequent infection rate with the same 
serotype (Hendley et al., 1969). However, the relative importance of serum and nasal 
antibodies in protection against the infection remains unclear. Neutralizing antibodies 
(IgA) have also been detected in tears and parotid saliva. 
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2.2.7.2 COMPLICATIONS OF RHINOVIRUS INFECTION 
 
While rhinovirus infections are typically mild and self-limiting illnesses, complications 
are not uncommon. Knowledge of these complications has greatly increased since the 
implementation of sensitive molecular-based techniques (RT-PCR) in the diagnosis of 
rhinoviruses. These complications have been the subject of a number of recent reviews 
(e.g. Pitkäranta & Hayden, 1998; Monto et al., 2001; Heikkinen & Jarvinen, 2003). 
 
Acute otitis media (AOM) is a frequent complication of a preceding or concomitant 
upper respiratory infection in children, as reviewed by Heikkinen and Chonmaitree 
(2003), and rhinoviruses have been identified as the most common respiratory viral 
pathogen associated with AOM in many studies (Arola et al., 1988, 1990a; Pitkäranta et 
al., 1998b; Vesa et al., 2001). The role of rhinoviruses in pathogenesis of otitis media 
with effusion (OME) is still uncertain. Rhinoviruses have been detected by both 
isolation and RT-PCR techniques in middle ear effusions of children with OME (Arola 
et al., 1990b; Pitkäranta et al., 1998a), but not in middle ear biopsies by in situ 
hybridization (Pitkäranta et al., 2002).  
 
Strong evidence suggests that rhinovirus infection is a major predisposing factor for 
acute community-acquired sinusitis (ACAS). Of adults with natural common colds, 42% 
had radiologically diagnosed ACAS on day seven of cold symptoms (Puhakka et al., 
1998). Furthermore, rhinovirus RNA was detected in maxillary aspirates of 8 out of 20 
patients with ACAS, suggesting that rhinoviruses in the sinus cavity are common in 
ACAS (Pitkäranta et al., 1997). This has later been supported by the detection of 
rhinovirus RNA inside epithelial cells of the maxillary sinus in 50% of patients with 
ACAS by in situ hybridization (Pitkäranta et al., 2001).  
 
Rhinovirus infections are associated with exacerbations of chronic respiratory diseases 
such as asthma (Gern, 2002), and chronic obstructive pulmonary disease (COPD) 
(Greenberg, 2002). The available data suggest that patients with asthma or COPD are no 
more susceptible to rhinovirus infection than the general population, but infections are 
more likely to predispose to more severe and longer-lasting lower respiratory symptoms 
(Hayden, 2004).    
 
In addition, rhinoviruses are the second, after respiratory syncytial virus, most common 
viral cause of small children being hospitalized due to bronchiolitis or pneumonia 
(Hayden, 2004; Papadopoulos, 2004). Rhinovirus infections are also associated with 
lower respiratory tract involvement and severe disease in immunocompromised patients. 
Seven of 22 myelosuppressed adult blood and bone marrow transplant recipients with 
rhinovirus infection developed fatal pneumonia (Ghosh et al., 1999). Rhinoviruses have 
also been detected by both culture (3/43 patients) and RT-PCR (5/43 patients) in 
bronchoalveolar lavage samples of patients with hematological cancer (van Elden et al., 
2002) and by RT-PCR in 8% of hematopoietic stem cell transplant recipients (Ison et 
al., 2003).  
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Rhinovirus infection may be a serious risk for elderly people (Falsey et al., 1997; Monto 
et al., 2001; Greenberg, 2002; Graat et al., 2003). In the community-dwelling elderly, 
lower respiratory tract symptoms were shown to occur in 63% of those with rhinovirus 
infection. The median duration of the illness was 16 days (Nicholson et al., 1996,1997), 
which exceeds the 9.5-11 days reported for younger adults (Arruda et al., 1997). 
Rhinovirus infection is also the reason for hospitalization of many of the elderly with 
underlying heart and lung problems (Falsey et al., 2002). Rhinovirus outbreaks in long-
term care facilities have been demonstrated to be a health risk for residents (Wald et al., 
1995). Rhinoviruses were isolated from 33 patients during a three-week autumn 
outbreak in a 685-bed long-term nursing home. Of the patients with a documented 
rhinovirus infection, 71% had systemic symptoms, 66% had lower respiratory symptoms 
and 52% had new abnormalities on lung auscultation. One patient died of respiratory 
failure (Wald et al., 1995). 
 
 
 
2.2.8 DIAGNOSIS OF RHINOVIRUS INFECTIONS 
  
 
2.2.8.1 VIRUS ISOLATION 
 
The traditional laboratory detection method for human rhinoviruses is isolation in cell 
culture (Couch, 1992). Rhinoviruses grow efficiently only in cell lines derived from 
human or other primate tissues, not in embryonated eggs or suckling mice. The 
susceptibility of different cell lines to rhinovirus serotypes varies considerably, the 
maximal isolation being obtained with combinations of human embryonic lung cells 
(WI-38 or MRC-5) and HeLa cells, which are selected for over-expression of ICAM-1 
(Arruda et al., 1996). Moreover, isolation of some rhinovirus strains has succeeded only 
after passaging in organ cultures or in volunteers (Larson et al., 1980). The optimal 
conditions proposed for rhinovirus isolation in cell cultures include a growth medium 
pH of 7.0-7.2, an incubation temperature of 33°C and slow rotation of cultures (Couch, 
1992). These recommendations are mainly based on practical experience obtained 
during first isolation attempts in human embryo kidney cells and have not been 
evaluated systematically. Some rhinovirus prototypes and wild-type strains have 
subsequently been shown to replicate as efficiently at 37°C as at 33°C, with the 
replication of certain wild-type strains being even better at 37°C (Papadopoulos et al., 
1999). Supplementing the growth media with Mg2+ ions is known to increase the 
recovery of some rhinovirus serotypes (Cooney & Kenny, 1977). Growth of the virus in 
cell monolayers is detected by the manifestation of cytopathic effects (CPEs). In 
spontaneously degenerating HeLa cells, a blind passage on day seven is usually needed 
for optimal virus recovery (Arruda et al., 1996). The CPE produced by rhinoviruses and 
enteroviruses is so similar that it can not be used for reliable differentiation of the two 
genera; instead, differentiation is accomplished by assaying the acid sensitivity of the 
viral isolates (Couch, 1992). 
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2.2.8.2 IDENTIFICATION OF RHINOVIRUS SEROTYPES 
 
Identification of the serotype of isolated rhinovirus strains can be performed with 
hyperimmune antisera produced in several animal species, including rabbits, guinea 
pigs, calves, goats and baboons. Because of the large number of rhinovirus serotypes, 
identification is usually done using a microneutralization assay with intersecting 
antiserum pools. The accepted standard for serological identity of an unknown 
rhinovirus is neutralization of virus concentrations ranging from 10 to 300 TCID50 by 20 
units of antibody. Neutralization is carried out at 33°C for two hours, and completion of 
the serotype identification assay takes 4-6 days (Gwaltney, 1966; Couch, 1992). 
 
 
2.2.8.3 ANTIGEN DETECTION 
 
Antigen detection methods are frequently used to identify many other respiratory 
viruses, but the large number of different rhinovirus serotypes hampers their use in 
rhinovirus detection. However, rhinovirus field strains from nasal samples and 11 
rhinovirus prototype strains were detected by immunofluorescent test using polyclonal 
antiserum to HRV2 after a 48-hour propagation of the viruses in cell culture (al-Mulla et 
al., 1994). The positive results were suggested to be due to a rhinovirus “common” 
antigen expressed some 48 hours after infection of HeLa Ohio cells with rhinoviruses, 
but the nature of this antigen remains unresolved.  
  
 
2.2.8.4 DETECTION OF VIRAL RNA  
 
The first rhinovirus RT-PCR assays were introduced in the late 1980s (Gama et al., 
1988, 1989; Hyypiä et al., 1989; Torgersen et al., 1989), when only a few picornavirus 
genomes were completely sequenced. The binding sites for oligonucleotide primers in 
most of the first, and also the present, rhinovirus RT-PCR assays are short, highly 
conserved stretches in the 5’ non-coding region (NCR), most of which are conserved 
also in enteroviruses (Rivera et al., 1988). These 5’ NCR RT-PCR assays have been 
shown to be highly sensitive, but the differentiation of rhinoviruses from enteroviruses 
requires such additional steps as restriction fragment length polymorphism (Torgersen et 
al., 1989), hybridization with rhinovirus-specific probes (Hyypiä et al., 1989; Johnston 
et al., 1993; Halonen et al., 1995; Lönnrot et al., 1999; Andreoletti et al., 000; Jenison 
et al., 2001), sequencing of PCR amplicons (Mori & Clewley, 1994) or semi-nested 
(Ireland et al., 1993) or nested PCR with rhinovirus-specific primers (Andeweg et al., 
1999; Steininger et al., 2001). Rhinoviruses and enteroviruses can be differentiated by 
the size of the RT-PCR amplicon when the RT-PCR is performed from the 5’ NCR to 
VP2 (or VP4) (Olive et al., 1990). While the sensitivity of this application is hindered 
by mismatches in the VP2 primer binding site (Santti et al., 1997; Hyypiä et al., 1998), 
it replaces the acid sensitivity test for clinical picornavirus isolates admirably (Atmar & 
Georghiou, 1993). Rhinovirus RNA can also be detected in situ either by hybridization 
with specific probes (Bardin et al., 1994; Pitkäranta et al., 2001) or by in situ RT-PCR 
(Bates et al., 1997). When tested in HRV16-infected HeLa cells, the sensitivity of in situ 
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RT-PCR was shown to be comparable with standard RT-PCR and greater than in situ 
hybridization for the detection of rhinovirus RNA (Bates et al., 1997). Nucleic acid 
sequence-based amplification (NASBA), an assay that directly amplifies the RNA, has 
also been demonstrated to be sensitive in detecting rhinovirus RNA (Samuelson et al., 
1998; Loens et al., 2003). Recently, a novel technique for quick RT-PCR, real-time 
PCR, was shown to sensitively detect rhinovirus RNA in three hours (Dagher et al., 
2004; Kares et al., 2004). In addition to real-time PCR being rapid, it enables the design 
of a quantitative application, but the assay demands special equipment not yet available 
in all laboratories performing rhinovirus diagnostics. 
 
 
2.2.8.5 DETECTION OF RHINOVIRUS-SPECIFIC ANTIBODIES  
 
The standard method for detecting rhinovirus-specific antibodies utilizes the ability of 
antibodies to neutralize homologous rhinovirus serotypes in cell cultures. The 
neutralization assay can be performed in either macro- (Douglas et al., 1968b) or 
microformat (Monto & Bryan, 1974). Rhinovirus antibodies can also be determined by 
complement fixation (Chapple et al., 1967) and haemagglutination inhibition (Reed & 
Hall, 1973) assays. An enzyme-linked immunoassay has been used to measure HRV2-
specific IgA and IgG antibodies in sera and nasal secretions (Barclay & Al-Nakib, 1987; 
Barclay et al., 1988).  
 
 
 
2.2.9 EPIDEMIOLOGY OF HUMAN RHINOVIRUSES 
  
 
2.2.9.1 GENERAL EPIDEMIOLOGY 
 
Most information on the occurrence of acute respiratory infections and the epidemiology 
of different causative agents comes from highly intensive longitudinal family and 
community studies conducted in the 1960s to 1980s (reviewed by Monto, 1994, 2002a). 
Selected studies in which rhinoviruses were specifically identified are presented in 
Table 4. In these, the detection of rhinoviruses was performed exclusively by virus 
isolation and assaying the acid sensitivity of isolated virus strains. Specimens were 
mostly collected only from persons experiencing acute respiratory symptoms (Hope-
Simpson & Higgins, 1969; Monto & Cavallaro, 1972; Monto et al., 1987), but in the 
New York and Seattle Virus Watches, samples were also routinely collected from 
healthy individuals (Ketler et al., 1969; Fox et al., 1975, 1985). These earlier studies 
that used virus isolation for rhinovirus detection probably greatly underestimated the 
prevalence of rhinoviruses. Comparisons between virus isolation and RT-PCR in 
rhinovirus detection have clearly demonstrated the superiority of the molecular methods 
(Arruda et al., 1997; Hyypiä et al., 1998). Monto (2002b) has suggested that the earlier 
isolation frequencies should be multiplied by a factor of 1.5-3 to obtain the actual rates 
of rhinovirus identification.  
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Rhinoviruses have been shown to be by far the most frequently isolated viruses from 
persons with symptoms of acute respiratory illness. Rhinovirus illnesses are common in 
all age groups, they occur throughout the year and they are present world-wide. In 
longitudinal family studies, which overcome age-dependent and seasonal variations, the 
overall rhinovirus isolation rate in persons with acute respiratory illnesses has varied 
from 6.1% (Monto et al., 1987) to 23.3% (Gwaltney et al., 1966). The rates are 
dependent on the type of specimens collected (Hendley et al., 1969) and the isolation 
method used (Cooney et al., 1972).  
 
The prevalence of rhinovirus antibodies in human sera is similar in different parts of the 
world, indicating the ubiquitous nature of these viruses (Taylor-Robinson, 1965). 
Antibodies to rhinoviruses have also been detected in people living in remote areas such 
as Micronesian islanders, North American Eskimos and South-West African aboriginals 
(Brown & Taylor-Robinson, 1966). In addition, neutralizing antibodies for seven out of 
nine tested rhinovirus serotypes were present in sera of an even more isolated primitive 
Indian tribe in the Southern Amazon Basin (Thwing et al., 1993). 
 
 
 
Table 4.  Selected epidemiological studies in which rhinovirus isolation was performed.  
 
 
 
Study name or site Period  Study population   References 
 
Chicago   1960 - 1964 100-200 young adults    Hamre et al. (1966) 
New York Virus Watch  1961 - 1965 average 40 families    Ketler et al. (1969) 
Cirencester Study  1961 - 1966 ca. 3500 persons        Hope-Simpson et al. (1969) 
Charlottesville - Virginia 1963 - 1966 320-570 adults     Gwaltney et al. (1966)  
Charlottesville - Virginia 1965 / 1966 50 / 69 families     Hendley et al. (1969) 
Seattle Virus Watch  I 1965 - 1969 110 families with children    Fox et al. (1975) 
Tecumseh - Michigan  1966 - 1971 families; ca. 1000 persons    Monto & Ullman (1974)  
Seattle Virus Watch II 1975 - 1979 228 families with children    Fox et al. (1985) 
Tecumseh - Michigan 1976 - 1981  families; ca. 1000 persons    Monto et al. (1987) 
 
 
 
2.2.9.2 TRANSMISSION 
 
 
Successful transmission of rhinovirus infection is dependent on the efficient entry of the 
virus into a susceptible recipient. Three routes, direct contact, indirect contact and 
aerosol, have been shown to be efficient in rhinovirus transmission in volunteer 
experiments, but the relative importance of these different routes in natural infections 
remains unknown (Jennings & Dick, 1987). Rhinovirus particles can be recovered from 
the hands of infected persons even if no respiratory symptoms are present  (Gwaltney et 
al., 1978). In the direct contact route, a brief 10-second hand-to-hand contact is 
REVIEW OF THE LITERATURE 
 
 
 
                                                         EPIDEMIOLOGY OF HUMAN RHINOVIRUSES                                                  28 
 
 
 
sufficient to transfer the particles onto the hands of the next person. Susceptible 
recipients become infected after placing contaminated fingers on their nasal or 
conjunctival mucosa (Hendley et al., 1973; Gwaltney et al., 1978). In indirect contact, 
the transmission involves contact with contaminated environmental objects. 
Rhinoviruses can survive on different objects, including drinking glasses, coffee cup 
handles and door knobs, for hours to days, and the contamination of environmental 
surfaces and accidental self-inoculation provide the means for infection (Hendley et al., 
1973; Gwaltney & Hendley, 1982). This kind of indirect transmission can be interrupted 
by treating surfaces of contaminated objects with disinfectants such as phenol/alcohol 
sprays (Gwaltney & Hendley, 1982). The third mode of rhinovirus transmission is by 
infectious aerosols composed of either large or small particles, but the results from the 
studies of aerosol transmission are quite discrepant. These airborne particles are 
produced by coughing, sneezing, talking or other similar activities of the infected 
person, and they come primarily from the salivary pool in the mouth, where the 
rhinovirus concentration is usually low (the virus is found in the saliva of only 50% of 
infected persons), and not from the nasal secretions with high virus titres (Gwaltney & 
Hendley, 1978). The experimental transmission of rhinovirus strain Hanks by large-
particle aerosol was very inefficient, and no transmission was accomplished by small-
particle aerosol (Gwaltney et al., 1978).  However, the transmission of rhinovirus type 
16 was clearly more efficient by aerosol than by direct or indirect contact (Dick et al., 
1987).  
 
Rhinoviruses spread most efficiently within families but frequently also in school 
groups, among university students and on military bases. The design of the Virus Watch 
family studies has provided a model to study the spread of rhinoviruses within families 
(Fox et al., 1975, 1985). By definition, the person whose excretion of rhinovirus or 
onset of the illness gives the first evidence of rhinovirus infection in the family is the 
introducer. The introduction rate has been shown to vary inversely with age (Hendley et 
al., 1969; Ketler et al., 1969; Fox et al., 1985). In the Seattle families (1965-1969) up to 
50% of family episodes were initiated by children of less than two years of age. The 
next most common introducers were pre-school children and mothers, while fathers had 
the lowest introducer rate (Fox et al., 1975).  Small children have been suggested to  
acquire their first infection from such sources as baby-sitters, guests or playmates of 
their older siblings (Fox et al., 1975). 
 
The frequency of secondary rhinovirus episodes varies directly with the family size (Fox 
et al., 1985). In rhinovirus-associated family episodes of illness, the onset of most of the 
secondary cases is within the first six days (Ketler et al., 1969). Small children 
effectively introduce the virus to siblings under the age of ten years and to their mothers 
(Ketler et al., 1969; Fox et al., 1985). Subclinical infections are much less effective 
sources of virus spread in families than symptomatic infections (Ketler et al., 1969).  
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2.2.9.3 AGE-DEPENDENT VARIATION   
 
Rhinovirus infections are especially common in children, as shown in many studies 
(Hope-Simpson & Higgins, 1969; Monto & Ullman, 1974; Fox et al., 1975, 1985; 
Monto et al., 1987). In the Seattle families, the mean number of rhinovirus isolations 
per person-year was highest in children aged 0-1 years (0.84) (Fox et al., 1975) or under 
5 years (0.85) (Fox et al., 1985). By two years of age, 86% of children had experienced 
at least one rhinovirus infection (Fox et al., 1975). Typically, the rate of rhinovirus 
infections is inversely related to age, with the exception of the age group 20-29 years 
(Monto et al., 1987). The increase in this age group is thought to be related to exposure 
of parents to young children (Monto et al., 1987). Recently, a high prevalence of 
rhinovirus infections has also been demonstrated among the elderly living in the 
community. Rhinoviruses were detected by RT-PCR in 32% of acute upper respiratory 
infection cases in persons 60 years of age or older (Corne et al., 2002). 
 
 
2.2.9.4 SEASONAL VARIATION  
 
Rhinovirus infections occur throughout the year, but pronounced seasonal patterns are 
seen depending on the type of climate. In the temperate climates of the Northern 
Hemisphere, the incidence of rhinovirus infections typically peaks during autumn and 
spring (Hamre et al., 1966), the isolation rate varying from 0% to 70% in different 
seasons (Gwaltney et al., 1966). The relative prominence of the autumn and spring 
peaks has varied depending on the study. The highest incidence of rhinovirus infections 
has been found in September, followed by October, (Gwaltney et al., 1966; Monto et 
al., 1987) or, alternatively, in May (Fox et al., 1975, 1985). During the autumn 
rhinoviruses comprise 80-90% of all common colds (Arruda et al., 1997; Mäkelä et al., 
1998). The overall rates of respiratory illness are low in summer, but rhinoviruses are 
also isolated during the summer months and are responsible for most of the illnesses in 
this period (reviewed by Monto, 2002b). Few studies have been conducted in other 
climate types. However, in tropical climates, respiratory infections seem to peak 
simultaneously with the most intense rainfall, i.e. at the beginning and the end of the 
rainy season (Monto & Johnson, 1967, 1968).  
 
The reasons for the seasonal behaviour of rhinoviruses are not well understood.  
Attempts to demonstrate a relationship between exposure to a cold environment and 
contracting a common cold have failed (Douglas et al., 1968a). Rhinoviruses, as well as 
other picornaviruses, survive better in an environment in which the relative humidity is 
greater than 50% (reviewed by Hendley & Gwaltney, 1988), and an indoor relative 
humidity effect on virus survival has been proposed to be one important variable in 
determining the seasonality. The autumn peak coincides with the beginning of school, 
which certainly enhances the means for efficient transmission. However, if the high 
prevalence of rhinoviruses in autumn is a consequence of increased indoor crowding, 
then the spring peak would have a different, still unresolved, explanation.  
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2.2.9.5 PREVALENCE OF SPECIFIC RHINOVIRUS SEROTYPES  
 
Studies in which the serotypes of isolated rhinoviruses have been identified are rather 
sparse (Table 5). Most of the rhinovirus isolates with a confirmed serotype are from 
epidemiological studies conducted in the United States before 1980s (Table 4), with the 
strains being isolated mainly from community-dwelling children or adults with upper 
respiratory symptoms. The rhinovirus strains isolated in Boston (Krilov et al., 1986) and 
Vienna (Kellner et al., 1991), by contrast, are exclusively from children hospitalized due 
to severe lower respiratory symptoms. The isolates from Moscow and Prague are from 
children or adults with upper or lower respiratory symptoms. The serotypes of all of the 
isolates shown in Table 5 were confirmed with antisera to serotypes HRV1A to HRV89, 
but in addition to the successfully typed strains, over 100 strains have remained 
untypeable in these studies. Some of the untypeable strains were included in Phase III of 
the Rhinovirus Collaborative Programme (Hamparian et al., 1987) and assigned 
serotype numbers from HRV90 to HRV100. Many strains are still unnumbered.  
 
The prevalence of distinct rhinovirus serotypes among a collection of 1582 strains 
(Table 5) is shown in Figure 3. In Seattle Virus Watch II, conducted during 1975-1979, 
nearly 600 rhinovirus strains were typed (Fox et al., 1985), but the serotype distribution 
is not available in the literature. The occurrence of different serotypes seems to be 
diverse, the number of isolations of a given type ranging from 0 (HRV17) to 58 
(HRV56). The prototype strain of HRV17, which is the only serotype with no confirmed 
subsequent isolations, has been shown to exhibit such rapid antigenic variation under 
immunological pressure in vitro that after a few serial passages the progeny viruses 
could not be classified as HRV17 (Patterson & Hamparian, 1997). If the virus has 
behaved similarly in nature, type HRV17 may no longer exist.  
 
 
Table 5.       Representative studies in which the serotypes of isolated rhinovirus strains 
were identified. Only studies in which serotype identification results could be readily 
found in the literature are included. 
 
 
Study     Study site  Study period Number  Reference 
       of isolates  
       
I  Glasgow, UK  1962-1966 71  Stott (1969) 
II  New York, USA  1963-1965 165  Fox et al. (1975) 
III  Charlottesville, USA 1963-1966 214  Gwaltney et al.(1968) 
IV  Prague, Czech Republic 1965-1976 63  Dreizin et al. (1979)   
V  Tecumseh, USA  1966-1971 250  Monto et al. (1987) 
VI  Seattle, USA  1966-1970 456  Fox et al. (1975) 
VII  Charlottesville, USA 1969-1970 58  Calhoun et al. (1974) 
VIII  Moscow, Soviet Union  1971-1974 61  Dreizin et al. (1979)    
IX  Tecumseh, USA  1976-1981 194  Monto et al. (1987) 
X  Boston, USA  1982  13  Krilov et al. (1986) 
XI  Wien, Austria  1986-1990 37  Kellner et al. (1991) 
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Figure 3.   Prevalence of rhinovirus serotypes. The epidemiological studies involved (I–
XI) are shown in Table 5.  
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The most “common” rhinovirus serotypes were sought in the 1960s and 1970s to enable 
the selection of these common strains for vaccine development (Fox et al., 1975). 
However, two studies performed in Tecumseh proposed that the prevalent serotypes 
change from year to year. Of the 14 common serotypes in 1966-1971, only four 
remained common in 1976-1981. Four of the common serotypes in 1976-1981 not  
appeared in 1966-1971 (Monto et al., 1987). However, some serotypes have been 
isolated more frequently than others. In the strain collection depicted in Figure 3, the 15 
most common types (isolated over 30 times) comprise 40% of the confirmed serotypes. 
All serotypes do not grow equally well in cell cultures, and the common serotypes may 
be those that grow better. The minor receptor group rhinoviruses have wider cell 
tropism than the major receptor group viruses, and may thus be more easily isolated. 
However, the prevalence of the minor group viruses seems only rarely to exceed that of 
the major group viruses (Dreizin et al., 1979). In Figure 3, the minor receptor group 
viruses (10/90 serotypes) account for 16% of the isolates. 
 
After the first large studies conducted in New York, Charlottesville, Tecumseh and 
Seattle, it was proposed that a shift occurs with time to higher numbered serotypes and 
possibly new, untypeable viruses. This was thought to be a reflection of a progressive 
antigenic shift (Monto & Cavallaro, 1972; Calhoun et al., 1974; Fox et al., 1975; Fox, 
1976). However, 92.8% of the isolates (194/209) from Tecumseh (1976-1981) could be 
typed with antisera representing types HRV1A to HRV89 (Monto et al., 1987).  
Similarily, the follow-up study in Seattle during 1975-1979 predicted that new serotypes 
will not continue to emerge in the same rate as before (Fox et al., 1985).  
 
A typical feature of the occurrence of rhinoviruses is that multiple distinct serotypes 
circulate simultaneously in a given population. Even in the same family, more than one 
serotype can be isolated (Hendley et al., 1969). Multiplicity of serotypes encountered is 
characteristic of the periods of increased rhinovirus incidence; for example, 10-15 
serotypes were circulating simultaneously in Seattle in April, May and September 1967 
and in May, September and October 1968 (Fox et al., 1975). The circulation of multiple 
serotypes can be readily seen in the follow-up studies. Rhinovirus  infections in young 
adults were related to 48 different serotypes over a three-year period (1963-1966) in 
Charlottesville, Virginia (Gwaltney et al., 1968). Fifty-eight different serotypes were 
isolated in the Seattle families followed from 1965 to 1969 (Fox et al., 1975). In 
Tecumseh, 53 different serotypes were identified from the 181 rhinoviruses isolated 
during 1966-1969 (Monto & Cavallaro, 1972).  Rhinoviruses can also appear as 
extensive outbreaks (e.g. HRV14 in Charlottesville in September 1965 (Gwaltney et al., 
1968) and HRV48 in Moscow in 1971 (Dreizin et al., 1979)), but during the outbreaks 
serotypes other than the most prominent ones are also frequently isolated. Rhinovirus 
serotypes can cause simultaneously numerous outbreaks over wide geographically 
distinct areas. Types HRV7, HRV23, HRV29, HRV38 and HRV39 were isolated in 
Glasgow during the same period as these types appeared most frequently in the United 
States (Stott, 1969). 
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Some of the rhinovirus serotypes have been identified in a given population in only a 
single seasonal epidemic; others have appeared for two or three consecutive years, some 
in alternate years (Gwaltney et al., 1968). Certain serotypes persist for longer periods. In 
Seattle in 1965-1969, over 50% of all serotypes were isolated for ten or more months - 
some of them up to 40 months (Fox et al., 1975). In Tecumseh, the time span of HRV15 
isolations reached 38 months (Monto & Cavallaro, 1972). In Prague, HRV31 was 
isolated for five successive years (Dreizin et al., 1979).  
 
Differences in infectivity of distinct rhinovirus serotypes were suggested several 
decades ago (Monto & Johnson, 1968; Stott, 1969), but the small number of typed 
rhinovirus isolates has made clinical comparisons difficult. Today, no clear indication of 
any relationship between the type of the rhinovirus isolated and the form of the disease 
has been obtained.  In Moscow, 97 rhinovirus strains isolated from adults or children 
suffering from different upper and lower respiratory tract symptoms were serotyped, but 
no correlation was found between the serotype and the illness (Dreizin et al., 1979). In 
Vienna, 49 rhinoviruses were isolated from nasopharyngeal secretions of children 
hospitalized due to severe lower respiratory tract infection (Kellner et al., 1991). 
HRV30 was more frequently isolated in children with lower respiratory tract infection 
without a spastic component, while serotypes HRV40 and HRV50 were prevalent in 
those with severe obstructive airway disease. However, the correlations between a 
specific serotype and a specific diagnosis were not statistically significant.  Interestingly, 
the only other isolates of HRV40 and HRV50 (Figure 3) were also isolated from 
children hospitalized for severe acute respiratory illness (Stott et al., 1969). 
 
The serotype-specific occurrence of rhinoviruses has also been studied by determining 
the prevalence of neutralizing antibodies to serotypes HRV1A through HRV55. In sera 
from 148 adults, antibodies were present to all serotypes tested, the prevalence ranging 
from 10% to 80%. No sharp division was present between types associated with high or 
low prevalence, but of the eight serotypes with the highest antibody prevalence, seven 
belonged to the minor receptor group (HRV1A, HRV1B, HRV2, HRV30, HRV31, 
HRV47, HRV49), the only major group serotype being HRV23 (Gwaltney, 1997). 
 
 
2.2.9.6 MOLECULAR EPIDEMIOLOGY 
 
Rhinoviruses, like other RNA viruses, are predisposed to extensive genetic variation 
mostly due to the lack of proofreading activity of the RNA-dependent RNA polymerase 
catalysing the synthesis of viral RNA. The rapid replication cycle and high mutation 
frequency of picornaviruses result in the existence of virus mixtures or quasi-species, in 
which the variants differ from each other by one or two bases (Domingo et al., 2001). 
Variation in picornavirus genomes is also enhanced by recombination, i.e. exchange of 
genomic material between two RNA genomes replicating in the same cell (Agol, 1997). 
Both intra- and interserotypic recombination is common in polioviruses (Cammack et 
al., 1988; Kew et al., 1995) and enteroviruses in HEV-B species (Santti et al., 1999; 
Lindberg et al., 2003). The recombination sites are usually located in the genomic 
region encoding non-structural proteins, but have also occasionally been found in the 
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VP1 capsid protein-coding region (Martin et al., 2002; Blomqvist et al., 2003). The high 
mutation frequency and recombination may be advantageous to viruses, enabling their 
rapid adaptation to changing environmental conditions.  
 
Studies of genetic variation in rhinoviruses are rare, although molecular methods, such 
as partial genome sequencing and sequence comparisons, are widely used in molecular 
epidemiological studies of other picornaviruses (Rodrigo & Dopazo, 1995; Oberste et 
al., 2003; Hughes, 2004). In rhinovirus research, molecular methods have thus far 
mainly been used in detection of rhinovirus RNA (RT-PCR), in attempts to identify 
distinct rhinovirus serotypes by restriction fragment length polymorphism (Torgersen et 
al., 1989) and in evaluation of the genetic relationships between rhinovirus prototype 
strains.  
 
The first attempt to analyse the molecular relationships of 54 different rhinovirus 
serotypes was performed in 1986 (Al-Nakib et al., 1986), when the complete genomic 
sequence was available for only HRV14 (Stanway et al., 1984). The cDNA probe 
constructed from the 5’ NCR of HRV14 was shown to give a positive hybridization 
signal with 54 of the 56 tested prototype strains, and the strength of the signal varied 
independently of the virus titre. HRV3, HRV4, HRV17 and HRV72 were suggested to 
be the closest relatives of HRV14. The clustering of rhinoviruses into different genetic 
groups was first proposed in 1987, when three prototype strains (HRV2, HRV14, 
HRV89) were completely sequenced (Duechler et al., 1987). Clustering into two 
genetically distinct groups was obvious also in comparisons of partial 5’ NCR 
sequences of 19 additional HRV prototype strains  (Mori & Clewley, 1994; Andeweg et 
al., 1999) and 30 clinical HRV strains (Andeweg et al., 1999). HRV87 was the only 
rhinovirus prototype that formed a cluster of its own in the 5’ NCR analysis (Andeweg 
et al., 1999).  
 
The greatest genetic variation in picornaviruses is seen in the capsid protein-coding 
region (Palmenberg, 1989), and the sequence of VP1 capsid protein has been 
demonstrated to correlate well with serotype in enteroviruses (Oberste et al., 1999). 
Molecular relationships of 21 HRV serotypes were analysed by partially sequencing the 
genomic region encoding the VP2 capsid protein (Horsnell et al., 1995). The sequenced 
region included one of the major immunogenic sites of rhinoviruses, NimII, also known 
as Site B (Sherry et al., 1986, 1987). The two genetic groups were again observed. In 
addition, some pairs or triplets of the serotypes (HRV1A and HRV1B; HRV2 and 
HRV49; HRV36, HRV58 and HRV89) were shown to exhibit striking sequence 
similarity, correlating with the previously described antigenic relationships (Cooney et 
al., 1982). 
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3 AIMS OF THE STUDY 
   
 
 
The objective of the Finnish Otitis Media Cohort Study (FinOM Cohort), which was 
carried out in Tampere, Finland, in 1994-1997, was to investigate risk factors, including 
respiratory virus infections, for acute otitis media (AOM) in children less than two years 
of age. While laboratory methods for detection of most of the common respiratory 
viruses were readily available, those for detection of rhinoviruses were not established 
and required developmental work. This thesis is based on methodological and 
epidemiological studies of rhinoviruses in this context. 
 
The prospective study design of the FinOM Cohort enabled us to analyse the age-
dependent occurrence of rhinovirus infections during subjects’ first two years of life, 
with a special focus on AOM cases where specific clinical specimens, i.e. middle ear 
fluids and paired sera, were collected. Subsequent to the analysis of the overall 
prevalence of rhinovirus infections in the child cohort, we wanted to clarify which 
rhinoviruses were involved, and to determine this, we developed molecular tools for 
characterization of rhinovirus field strains. In the process of doing this, we discovered, 
that one of the rhinovirus prototype strains, HRV87, was genetically exceptional, and 
thus, it was given a special attention. 
 
   
 
 
SPECIFIC AIMS OF THE STUDY WERE AS FOLLOWS 
 
 
1.  To develop a specific and sensitive assay for detection of rhinoviruses in a large 
collection of clinical specimens from the FinOM Cohort Study.  
2.  To analyse the occurrence of rhinovirus infections in a cohort of young children. 
3.  To characterize the rhinovirus prototype and field strains by molecular methods.  
4.  To further characterize the exceptional rhinovirus serotype HRV87. 
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4 MATERIALS AND METHODS 
 
 
Detailed descriptions of the materials and methods used are given in the original 
publications (Studies I-IV) and references therein. Only a brief summary and some 
clarifying comments are provided here. 
 
 
4.1 CLINICAL SPECIMENS  
The clinical specimens, 2005 nasopharyngeal aspirates (NPA), 1140 middle ear fluids 
(MEF) and 1998 sera, were derived from the Finnish Otitis Media Cohort Study 
(FinOM Cohort) carried out from 1994 to 1997 in Tampere, Finland, by the National 
Public Health Institute in collaboration with the Health Centre of the City of Tampere. 
The study design and the sample collection procedures are described in detail elsewhere 
(Syrjanen et al., 2001; Vesa et al., 2001). Written informed consent was obtained from 
the parents of all participants. The study protocol and the consent form were approved 
by the Ethics Committees of the National Public Health Institute, Tampere Health 
Centre and Tampere University Hospital. 
  
 
4.2 DEFINITIONS 
Rhinovirus episode was defined as follows: The first rhinovirus-positive specimen of 
the child, either NPA or MEF, started the first rhinovirus episode, which continued for 
30 days. Any subsequent rhinovirus-positive specimen taken during this period were 
included in the same episode. Likewise, an AOM episode was designated to be a 30-day 
period commencing with a diagnosis of AOM. 
 
 
4.3 VIRUS STRAINS  
The rhinovirus prototype strains used in Studies I-IV are shown in Table 6. The 
prototype strains were either purchased from the American Type Culture Collection 
(ATCC; Manassas, VA, USA) or received as a gift from the Haartman Institute, 
University of Helsinki, Finland, Janssen Pharmaceuticals, Beerse, Belgium, or the 
National Institute for Public Health and the Environment, The Netherlands. HRV31 was 
also received from D. Blaas, University of Vienna, Austria. The unnumbered rhinovirus 
strain Hanks was kindly provided by F. Hayden, Charlottesville, VA, USA. Isolation of 
rhinovirus field strains is described in Study I. The rhinoviruses were passaged once or 
twice in HeLa Ohio cells before use in the experiments. The enterovirus prototype 
strains (I and IV) were originally obtained from the WHO Enterovirus Reference Centre, 
Copenhagen, Denmark, and made available by M. Stenvik (National Public Health 
Institute, Helsinki, Finland). 
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Table 6.  Human rhinovirus prototype strains used in Studies I-IV and their origin. 
 
Serotype Prototype  Origin*  (Study)  Serotype Prototype                 Origin* (Study)
 strain      strain     
 
1A Echo-28  RIVM (III)  51 F01-4081  RIVM (III) 
1B B632  HI (I); RIVM (III,IV) 52 F01-3772  RIVM (III) 
2 HGP  HI (I)   53 F01-3928  RIVM (III) 
3 FEB  RIVM (III)  54 F01-3774  RIVM (III) 
4 16/60  RIVM (III)  55 WIS 315E  RIVM (III) 
5 Norman  RIVM (III)  56 CH82   RIVM (III) 
6 Thompson RIVM (III)  57 CH47   Janssen (III) 
7 68-CV11  RIVM (III)  58 21-CV20   RIVM (III) 
8 MRH-CV12 ATCC (III)  59 611-CV35  RIVM (III) 
9 211-CV13 HI (I); RIVM (III)  60 2268-CV37  RIVM (III) 
10 204-CV14 RIVM (III)  61 6669-CV39  RIVM (III) 
11 1-CV15  HI (I); RIVM (III)  62 1963M-CV40  RIVM (III) 
12 181-CV6  HI (I); RIVM (III)  63 6360-CV41  RIVM (III) 
13 353  HI (I); RIVM (III)  64 6258-CV44  RIVM (III) 
14 1059  HI (I); RIVM (III,IV) 65 425-CV47  RIVM (III) 
15 1734  RIVM (III)  66 1983-CV48  RIVM (III) 
16 11757  ATCC (III)  67 1857-CV51  RIVM (III) 
17 33342  RIVM (III)  68 F02-2317-Wood  RIVM (III) 
18 5986-CV17 RIVM (III)  69 F02-2513-Mitchinson RIVM (III) 
19 6072-CV18 RIVM (III)  70 F02-2547-Treganza RIVM (III) 
20 15-CV19  ATCC (III)  71 SF365   RIVM (III) 
21 47-CV21  RIVM (III)  72 K2207   RIVM (III) 
22 127-CV22 RIVM (III)  73 107E   RIVM (III) 
23 5124-CV24 RIVM (III)  74 328A   RIVM (III) 
24 5146-CV25 RIVM (III)  75 328F   RIVM (III) 
25 5426-CV12 RIVM (III)  76 H00062   RIVM (III) 
26 5660-CV27 RIVM (III)  77 130-63   RIVM (III) 
27 5870-CV28 RIVM (III)  78 2030-65   RIVM (III) 
28 6101-CV29 RIVM (III)  79 101-1   RIVM (III) 
29 5582-CV30 HI (I); RIVM (III)  80 277G   Janssen (III) 
30 106F  RIVM (III)  81 483F2   Janssen (III) 
31 140F  RIVM (III); Vienna** 82 03647   Janssen (III) 
32 363  RIVM (III)  83 Baylor 7   Janssen (III) 
33 1200  RIVM (III)  84 432D   Janssen (III) 
34 137-3  RIVM (III)  85 50-525-CV54  Janssen (III) 
35 164A  ATCC (III)  86 121564-Johnson  Janssen (III) 
36 342H  RIVM (III)  87 F02-3607-Corn    Janssen (III);ATCC (IV) 
37 151-1  RIVM (III)  88 CVD-01-0165-Dambrauskas Janssen (III) 
38 CH79  HI (I)   89 41467-Gallo  Janssen (III) 
39 209  HI (I); RIVM (III)  90 K2305   Janssen (III) 
40 1794  RIVM (III)  91 JM1   Janssen (III) 
41 56110  RIVM (III)  92 SF-1662   Janssen (III) 
42 56822  RIVM (III)  93 SF-1492   Janssen (III) 
43 58750  ATCC (III)  94 SF-1803   Janssen (III) 
44 71560  Janssen (III)  95 SF-998   ATCC (III) 
45 Baylor 1  RIVM (III)  96 SF-1426   Janssen (III) 
46 Baylor 2  RIVM (III)  97 SF-1372   Janssen (III) 
47 Baylor 3  RIVM (III)  98 SF-4006   Janssen (III) 
48 1505  HI (I); RIVM (III)  99 604   Janssen (III) 
49 8213  RIVM (III)  100 K6579   Janssen (III) 
50 A2 No.58 RIVM (III)  unnumbered      Hanks  Charlottesville** 
 
*RIVM, National Institute for Public Health and the Environment, The Netherlands; HI, Haartman 
Institute, University of Helsinki, Finland; ATCC, American Type Culture Collection, Manassas, VA, 
USA; Janssen, Janssen Pharmaceuticals, Beerse, Belgium.  
**for origin, see text. 
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4.4 CELL LINES 
A rhinovirus-sensitive Ohio strain of the HeLa cell line was kindly provided by E. 
Arruda (University of Virginia, Charlottesville, VA, USA). The HeLa Ohio cells were 
maintained in Eagle’s Basal Medium (Life Technologies A/S, Roskilde, Denmark) as 
described in Study I. This cell line was used in passaging of rhinovirus prototype strains 
and also in isolation of rhinoviruses from clinical specimens (I-III). Enterovirus 
prototype strains (I, IV) were propagated in a human rhabdomyoma cell line, which was 
provided by M. A. Pallansch (Centers for Disease Control and Prevention, Atlanta, GA, 
USA). 
 
4.5 RHINOVIRUS ISOLATION IN CELL CULTURE  
The conventional rhinovirus isolation procedure for rolling tubes of HeLa Ohio cells 
(Couch, 1992) was used in method comparison (I) and in propagation of prototype and 
field strains of rhinoviruses (III). A microwell application of rhinovirus isolation was 
developed for the large number of specimens (II) and is described in detail in Study I. 
 
4.6 ASSAY FOR ACID SENSITIVITY  
Acid sensitivity of the isolated virus strains was assayed by a standard method (I, II) 
(Couch, 1992). In addition to the standard assay, a slightly different test procedure was 
employed in Study IV, which is described in the original publication (Schieble et al., 
1967). 
 
4.7 SEROLOGICAL ASSAYS 
Antibodies to a mixture of rhinovirus serotypes were measured using a complement-
fixation method (Hawkes, 1979), as described in Study II. The prevalence of 
neutralizing antibodies to HRV87 and EV68 in a collection of sera of adults (Study IV) 
was assayed by a microneutralization test (Couch, 1992).  
 
4.8 RNA ISOLATION 
Extraction of RNA from 100 l of clinical specimens or suspensions of infected cell 
cultures was performed by using a commercial RNA isolation kit (RNEasy, Qiagen 
GmbH, Hilden, Germany). After elution of RNA with ribonuclease-free water, 40 units 
of ribonuclease inhibitor (RNasin, Promega, Madison, WI, USA) were added. The RNA 
extracts were immediately frozen and stored at –80C until use. 
 
4.9 RT-PCR 
Procedures for cDNA synthesis (RT) and amplification (PCR) are described in detail in 
the original publications (I-IV). The RT and PCR reactions were performed as separate 
steps in microwell RT-PCR application (I, II) and in the RT-PCR preceding sequencing 
in Study III. In Study IV, all RT-PCR reactions were carried out in a single-tube 
procedure, as described in Oberste et al. (2000). The oligonucleotide primers and 
hybridization probes used in these studies are shown in Table 7. 
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4.10 DETECTION OF RT-PCR AMPLICONS 
The PCR amplicons were typically visualized after electrophoresis in an ethidium 
bromide-stained 2% agarose gel (I, III, IV). The rhinovirus-specific PCR amplicons 
from the 5’ non-coding region were recognized with a specific oligonucleotide probe 
(Table 5) using a microwell hybridization procedure as described in Study I. 
 
4.11 SEQUENCING 
The PCR amplicons were purified before use in sequencing by commercial kits 
(QIAquick, Qiagen), and the purified products were stored at –20C if not used directly 
in cycle sequencing (ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction 
Kit; Applied Biosystems, Espoo, Finland). An automated DNA sequencer model 377 
was used in Study III and the model 310 in Study IV. 
 
4.12 SEQUENCE ANALYSIS 
Primary sequence data were analysed with Sequencing Analysis (version 3.1, Applied 
Biosystems) and pair-wise comparisons were performed with Sequence Navigator 
(version 1, Applied Biosystems). Multiple sequence alignments were made with 
ClustalX version 1.64b (Thompson et al., 1997). The programs DNAdist and PROTdist 
from PHYLIP (Phylogeny Inference Package, version 3.572c, (Felsenstein, 1993)) were 
used for calculating distance matrices for DNA and proteins, respectively. The 
neighbour-joining option and maximum-likelihood model of nucleotide substitution in 
the Neighbor program (PHYLIP) were used for generation of the dendrograms. The 
phylogenetic trees were visualized with Njplot (Perriere & Gouy, 1996). Bootstrap 
analysis (Study III) was performed using Seqboot (PHYLIP) with 100 or 1000 
replicates.  
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5 RESULTS AND DISCUSSION 
 
 
 
5.1 DEVELOPMENT OF DIAGNOSTIC ASSAYS FOR HUMAN RHINOVIRUSES (I, II) 
 
 
The “gold standard” for rhinovirus detection has been virus isolation in susceptible 
rolling tube cell cultures (Couch, 1992). This method is extremely laborious, especially 
when large numbers of samples are to be analysed. To develop an easy-to-perform but 
sensitive rhinovirus detection method for large numbers of clinical specimens - more 
than 3000 in the FinOM Cohort Study - we employed two different approaches. First,  to 
overcome the tediousness of handling the tube cultures, we developed a rhinovirus 
isolation assay in HeLa Ohio microwell monolayers. Second, we applied a microwell 
RT-PCR assay followed by HRV-specific oligonucleotide probe hybridization for 
detection of  rhinovirus RNA directly from the clinical specimens or cell culture 
harvests. A comparison of the different methods for detecting rhinoviruses or rhinovirus 
RNA in a subset of 203 NPA specimens selected from the FinOM Cohort Study is 
shown in Table 8. 
 
 
 
 
Table 8. Comparison of different methods for detecting rhinoviruses or rhinoviral RNA 
in 203 nasopharyngeal (NPA) specimens. 
 
 
 
 
Number / percentage of rhinovirus-positive specimens 
 
Virus isolation  Virus isolation  RT-PCR on  RT-PCR on 
by tube culture  by microwell culture NPA specimens  cell culture harvests 
 
52 / 25.6   17 / 8.4   98 / 48.3   67 / 33.0  
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5.1.1 REMARKS ON VIRUS ISOLATION  
 
 
In microwell isolation, HeLa Ohio cell monolayers in 96-well microtitre plates were 
inoculated with the specimens, after which the plate was centrifuged to facilitate 
rhinovirus uptake. Before Study I and analysis of the large collection of clinical 
specimens from the FinOM Cohort Study, the sensitivity of the microwell culture assay 
was evaluated with 12 rhinovirus prototype strains and found to be equal to that 
obtained in rolling tube cultures (data not shown). In Study I, which was mainly aimed 
at evaluating the adequacy of the microwell RT-PCR assay, the two isolation procedures 
were compared using 203 NPA specimens selected from the FinOM Cohort Study. Of 
these specimens, 52 (25.6%) were rhinovirus-positive in the rolling tube isolation and 
only 17 (8.4%) in the microwell isolation. This comparison was performed only after 
analysing all clinical specimens from the FinOM Cohort Study. Altogether, of the 3145 
FinOM Cohort specimens (2005 NPA and 1140 MEF)  analysed by microwell isolation 
assay, 59 were found to be rhinovirus-positive (II). This positivity rate (ca. 2 %) was 
unexpectedly low and showed that the sensitivity of the microwell isolation method in 
practice is far from optimal. It seems that the successful isolation of rhinoviruses from 
clinical specimens requires the rolling tube conditions, although the prototype strains 
with long passaging history appear to grow as well in stationary as in rolling cell 
cultures. Another factor contributing to the overall low positivity rate may be the use of 
only one cell line. The relative insensitivity of a single cell line has been noted before. In 
comparising 3-5 different cell lines, single cell lines could detect 38-94% of HRV-
positive specimens. The best sensitivities (86-94%) were obtained with an ICAM-1-
overexpressing HeLa cell line (Arruda et al., 1996).    
 
 
 
5.1.2 MICROWELL RT-PCR HYBRIDISATION 
  
 
In the microwell RT-PCR hybridization assay, all steps after the initial RNA isolation 
can be performed in 96-well plates using multi-channel micropipettes, which enables the 
analysis of a large number of specimens simultaneously. Compared with virus isolation, 
a considerably higher rhinovirus positivity rate (48.3%), was obtained with the direct 
RT-PCR hybridization assay described in Study I. When the first-passage cell culture 
harvests were analysed, the positivity dropped to 33% but was nevertheless much higher 
than in either of the cell culture procedures. This improvement in sensitivity is in 
accordance with other studies. Compared with rhinovirus isolation in cell culture, all 
published rhinovirus RT-PCR assays have increased the sensitivity of rhinovirus 
detection (e.g. Ireland et al., 1993; Johnston et al., 1993). Of the 69 NPA specimens 
studied by Lönnrot et al. (1999), six were shown to be positive by isolation and an 
additional ten by RT-PCR. Of 400 NPA specimens collected from 200 adults on the first 
and seventh days after onset of a common cold, 127 NPA samples were positive in virus 
isolation and 186 in RT-PCR (Hyypiä et al., 1998). Nested rhinovirus RT-PCR detected 
rhinovirus RNA in 23.5-23.9% of a set of clinical samples, while only 3.5-6.3% were 
positive in isolation (Andeweg et al., 1999). The sensitivity of RT-PCR has also been 
RESULTS AND DISCUSSION 
 
                                                            EPIDEMIOLOGY OF HUMAN RHINOVIRUSES                                    43  
demonstrated in routine diagnostics. Six out of 229 respiratory specimens analysed 
during a five-year period were positive for rhinovirus by virus culture compared with 24 
by RT-PCR (Vuorinen et al., 2003). 
 
The specificity of our RT-PCR hybridization assay was first evaluated with 11 
rhinovirus and 17 enterovirus prototype strains (Study I). All except one of the tested 
prototype strains were successfully amplified, as evidenced by clearly visible RT-PCR 
amplicons in a 2% agarose gel. The exception was echovirus 22, which has been re-
assigned to parechovirus 1 (Hyypiä et al., 1992; Stanway & Hyypiä, 1999) and is no 
longer classified as a member of human enteroviruses (King, 2000). In the hybridization 
assay, the dinitrophenyl (DNP)-labelled HRV-specific oligonucleotide probe recognized 
all of the rhinovirus strains and none of the enterovirus strains. Since Study I we have 
tested all officially recognized rhinovirus and enterovirus prototype strains with the 
same primer-probe combination (Nokso-Koivisto et al., 2002). Of the 102 rhinovirus 
stains, 96 were recognized with the probe, but again, none of the enterovirus or 
parechovirus prototype strains gave a positive signal. Rhinovirus prototype strains 
HRV12, HRV45, HRV51, HRV65, HRV71 and HRV87 were negative with the HRV 
probe, although they were successfully amplified in the RT-PCR. HRV87 has 
subsequently been classified as a member of human enteroviruses (III and IV). The 
reason for the negative result for the other strains is probably a sequence mismatch in 
the probing region of the viral genome.  
 
Although the RT-PCR hybridization assay used detected rhinoviruses with much greater 
sensitivity than either of the cell culture isolation methods, some of the rhinovirus 
strains went undetected. Eight of the 52 culture-positive specimens in the 203 NPA 
collection were negative in RT-PCR hybridization (I), and of the complete set of 3145 
FinOM Cohort specimens, 16 were positive in virus isolation only (II). These PCR-
negative strains might resemble the serotypes that were negative with the HRV probe in 
the prototype evaluation (see above). Alternatively, they might represent acid-sensitive 
enterovirus strains like HRV87 and EV68 (III and IV).  
 
Until recently, very little has been known about the molecular evolution of circulating 
rhinovirus strains. Today, partial or complete 5’ NCR sequences for 42 rhinovirus 
prototype and 95 clinical strains are available in GenBank (Andeweg et al., 1999; Loens 
et al., 2003; Deffernez et al., 2004). Our HRV primer and probe sequences are covered 
at least partially by 27 prototype and 45 clinical sequences available and are compared 
in Figure 4. The sequences of the prototype strains HRV13, HRV27, HRV43 and 
HRV45 submitted to GenBank under accession numbers AF542449-AF542452 (Loens 
et al., 2003) are not included in the comparison, because these sequences are 100% 
identical to each other and 99%  identical to poliovirus 1 (PV1) strain Brunhilde, 
suggesting contamination of all of these rhinovirus stocks with PV1 (Davies et al., 
2003; Savolainen & Hovi, 2003). As can be seen in the alignment, our primer sequences 
match almost perfectly with the sequences retrieved from GenBank. There are one to 
three base substitutions in five and three prototype strain sequences in the forward and 
reverse primer regions, respectively. Despite this, these strains were amplified in our 
RT-PCR. If the sequence mismatches are real, the sensitivity of the assay in detecting 
RNA of these rhinovirus strains may be decreased (not tested). The part of the 5’ NCR 
selected for the HRV probe attachment is more complicated. HRV51 and two clinical 
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isolates have a one-base deletion in the middle of the probing region, which probably 
explains why prototype strain HRV51 was not recognized by the probe. Sequences for 
the other prototype strains not recognized by the probe are not yet available. The probe 
is identical to the corresponding sequences in 9 of the 27 prototype and 8 of the 45 
clinical rhinovirus strains. Other prototype sequences have one or two base 
substitutions, which seems to be acceptable in the assay conditions that we used. 
HRV87, the only prototype strain with three substitutions, was not recognized with the 
probe. The sequences of the clinical strains mostly have only one mismatch, but some 
strains have three or four substitutions. Although we have not ascertained this, most 
probably the strains with the greatest variation (three or four mismatches) would have 
gone undetected in our assay conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. ClustalX alignment showing the differences between the HRV primer and 
probe sequences used in Studies I and II and those of other published 5’ NCR 
sequences.  (a) Sequences encompassing the HRV 1 antisense primer sequence are 
shown in the length found in GenBank.  The GenBank accession numbers and 
references for the sequences are as follows:  (b) AF542419 – AF542448 (Loens et al., 
2003), (c) AF108149 – AF108187 (Andeweg et al., 1999),  (d) AY062273 (Study IV), 
(e) NC_001752 (Lee et al., 1995), (f) (Knowles, 1996), (g) X02316 (Skern et al., 1985), 
(h) A10937 (Duechler et al., 1987), (i) NC_001435 (Hughes et al., 1988), (j) 
NC_001490 (Stanway et al., 984).  
 
* stands for a deletion.  
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93-04433(c)     ------------------ 
MI97058122(b)   ---------T-------- 
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HRV strain             HRV 2 sense primer                     HRV probe                                  HRV 1 antisense primer (a)  
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5.2 OCCURRENCE OF RHINOVIRUS INFECTIONS DURING THE FIRST TWO YEARS 
OF LIFE (II) 
 
 
The occurrence of rhinovirus infections was studied in a cohort of 329 children (FinOM 
Cohort Study) during the first two years of life. Rhinovirus detection comprised a 
combination of virus isolation in microwell HeLa Ohio cell monolayers and an RT-PCR 
hybridization assay on the inoculated cell cultures (described in Study I). The detection 
attempts were made on nasopharyngeal samples collected in every case of upper 
respiratory infection, whether the child had AOM or not. In the cases of AOM, middle 
ear fluid (MEF) specimens were also collected and analysed. Serological analysis of 
rhinovirus infections was performed by measuring complement-fixing antibodies to a 
mixture of 11 rhinovirus serotypes. Paired sera were collected from AOM cases and 
four  scheduled serum specimens were drawn from all children.  
 
In the cohort of 329 children, altogether 544 rhinovirus episodes were detected by 
virological methods. Two hundred and twenty-three children (68%) had at least one 
rhinovirus episode during the study period, the highest number of episodes per child 
being eight. Rhinovirus infections were shown to start already during the first months of 
life; the youngest child with documented rhinovirus-related illness was seven weeks (51 
days) old. The median age of the children at the onset of the first rhinovirus episode was 
246 days. The highest incidence of rhinovirus episodes (>8.5 episodes/100 child-
months) was observed in children aged 7-15 months, thereafter the incidence slowly 
decreased. More than 20% of the children had experienced their first rhinovirus 
infection by the age of six months, as detected by virus isolation or PCR, and 23.8%  
had rhinovirus-specific antibodies by that time. At the age of two years, 91.3% were 
seropositive, and at least one rhinovirus infection was detected by virological methods 
from 79.0% . These latter figures are in accord with the observation in the Seattle Virus 
Watch, that 86% of children had experienced a rhinovirus infection by two years of age, 
as detected by virus isolation (Fox et al., 1975). 
 
Rhinovirus infections were studied by both virological and serological methods in 458 
episodes of AOM. Forty-one per cent of the AOM episodes were positive for rhinovirus 
when assayed by isolation and/or RT-PCR, while a significant antibody titre increase in 
paired sera was detected in only 7% of AOM episodes. The proportion of virologically 
confirmed rhinovirus-positive AOM episodes was higher than in previous reports. Arola 
et al. (1988) detected rhinovirus by virus isolation in 8% of MEF samples, with 17% of 
AOM cases being positive for rhinovirus. Of 363 children followed prospectively for 
one year, 24% had a rhinovirus-positive AOM episode, as determined by virus isolation 
from NPA specimens (Arola et al., 1990a). By RT-PCR, rhinovirus was detected in 
35% of the 92 children with AOM (Pitkäranta et al., 1998b).  
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Serological tests are rarely used in the diagnosis of rhinovirus infections because of their 
poor sensitivity. We tried to improve the conventional complement fixation (CF) test by 
heating and mixing 11 different rhinovirus serotypes into the antigen preparation, and  
most children did show a seroconversion to the antigen during the first two years of life. 
However, even using this antigen preparation in the diagnosis of acute rhinovirus 
infections, the virological methods proved to be much more sensitive.  
 
The virological findings in the FinOM Cohort Study have been reported in detail 
elsewhere (Vesa et al., 2001; Nokso-Koivisto et al., 2004). In the FinOM Cohort Study, 
rhinoviruses were clearly the most frequently found viruses in the cases of acute upper 
respiratory infections and/or AOM. The occurrence of rhinovirus infections in children 
was shown to follow the seasonal patterns previously demonstrated in temperate 
climates. Rhinovirus infections were prevalent throughout the year, but the most 
pronounced peaks were seen in spring and autumn (Figure 5). Of the two years with 
complete seasonal data, the spring peak (March) was most prominent in 1995, and the 
autumn peak (August) in 1996. The seasonal variation in the occurrence of rhinoviruses 
coincided with the variation in AOM episodes.  This continued in the FinOM Vaccine 
Trial, conducted after the FinOM Cohort Study, and described by Nokso-Koivisto et al. 
(2004). The typical seasonal patterns of rhinovirus prevalence in temperate climates also 
reflect another feature frequently associatiated with rhinovirus infections; the occurrence 
of asthma exacerbations with hospital admission was shown to be highest in the autumn 
and spring, and the relationship was stronger for pediatric admissions (Johnston et al., 
1996).  
 
 
 
 
 
 
 
 
 
Figure 5.   Seasonal variation of rhinovirus-specific  (     ) and AOM  (         ) 
episodes in the FinOM Cohort Study, expressed as monthly rates per 100 children. The 
figure is adapted from Vesa et al. (2001) with a kind permission of the publisher. 
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5.3 GENETIC ANALYSIS OF RHINOVIRUS STRAINS (III) 
 
The virological (virus isolation and RT-PCR) and serological methods described in 
Studies I and II recognize the rhinoviruses as a group and do not separate individual 
rhinovirus strains with differences in, for example, pathogenicity. Recently, molecular 
methods have successfully been used in rapid genetic identification of circulating human 
enterovirus strains (Oberste et al., 2000), and this prompted us to explore the possibility 
of genetic typing of HRV field strains. 
 
To prepare tools for molecular characterization of rhinovirus field strains, we sequenced 
the complete VP4 and partial VP2 capsid protein-coding regions from all previously 
non-sequenced 97 rhinovirus prototype strains. For phylogenetic analysis, the 
corresponding sequences of HRV1B, HRV2, HRV14, HRV16 and HRV89 were 
obtained from GenBank. Prototype strain HRV31, used in Study III, was later found to 
be contaminated with strain HRV32 (Vlasak et al., 2003). The revised sequence of 
HRV31 was submitted to GenBank (AF343583) in June 2003. The phylogenetic 
analysis of the rhinovirus prototype strains (with the revised HRV31 sequence) is shown 
in Figure 6. The sequences of all but one of the prototype strains clustered into the two 
previously described phylogenetic clades (Duechler et al., 1987; Horsnell et al., 1995), 
with 76 serotypes in the HRV1B-related group (HRV-A) and 25 in the HRV14-related 
group (HRV-B). HRV87, the only exception, appeared to belong to the enterovirus 
species HEV-D.  
 
All ten rhinovirus serotypes known to belong to the minor receptor group (Uncapher et 
al., 1991) clustered into the genetic group HRV-A. They did not form a distinct 
subcluster of their own, instead being located in three different branches among the 
major receptor group rhinoviruses. Also found in the same “minor receptor branches” 
were the serotypes HR23 and HRV25, whose classification into the major receptor 
group has previously been questioned  (Crump et al., 1993). The same tripartite 
clustering of minor receptor group viruses was later also seen in the VP1 capsid protein 
region  (Vlasak et al., 2003; Ledford et al., 2004; Laine et al., submitted). 
 
The known antigenic sites of rhinoviruses do not involve the amino acids from the 
VP4/VP2 region analysed in this study (Sherry & Rueckert, 1985; Sherry et al., 1986; 
Skern et al., 1987; Verdaguer et al., 2000). However, most of the pairs of rhinovirus 
serotypes previously shown to have reciprocal antigenic relationships (Cooney et al., 
1973, 1982) cluster very close to each other in the phylogenic tree. Antigenic relatives 
HRV12 and HRV78 seem to be the only exceptions, with the strains clustering in 
distinct branches in the HRV-A group. Rhinovirus strains with one-way antigenic 
relationships (Cooney & Kenny, 1970; Calhoun et al., 1974; Cooney et al., 1982) are 
genetically not so closely related, but they do always cluster within the same genetic 
group, HRV-A or HRV-B. 
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Figure 6. A neighbour-joining tree showing the phylogenetic clustering of all rhinovirus 
prototype strains. Clustering of the rhinovirus strains supposed to belong to the minor 
receptor group of rhinoviruses is indicated in blue. Rhinovirus type 87 is shown in 
green. The bar indicates the genetic distance.  
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Recently, the genetic relationships of both rhinovirus prototype and field strains were 
studied also in the genomic region encoding non-structural proteins (Savolainen et al., 
2004). The same clustering into two genetic groups, HRV-A and HRV-B, was observed 
in the 3D polymerase coding gene, in addition to a third distinctly different cluster. 
Based on the phylogenetic analysis, the authors proposed that within-species 
recombination events occurred during the evolution of rhinoviruses. 
 
The phylogenetic analysis was broadened to also include the 61 previously sequenced 
rhinovirus field isolates from the FinOM Cohort Study. Of these 61 field strains, 24 
clustered into HRV-A and 37 into HRV-B, as previously described by Savolainen et al., 
(2002). This distribution was strikingly different from that seen within the prototype 
strains (A:B ratio 3:1) or within the field strains serotyped some decades ago (Figure 3, 
A:B ratio 1301:159 or about 8:1). However, because only a minor subset of rhinovirus-
positive specimens (61/833) from the FinOM Cohort were subjected to sequencing, the 
distribution of the analysed field strains probably does not indicate the actual prevalence 
of circulating HRV-A and HRV-B strains. Most of the field strains had more than 90% 
identical nucleotides with the nearest prototype strain, and they could be easily linked to 
a single prototype. In this respect at least, the VP4/VP2 coding region can be used to 
genotype field strains. However, for enteroviruses, sequence comparisons in the VP1 
region give more reliable serotype identification than those in the VP4/VP2 region 
(Oberste et al., 1999), and whether this also applies to rhinoviruses remains to be 
analysed. Considering the laborious serotype identification with the conventional 
neutralization assays and the known antigenic variation in rhinoviruses, genetic typing 
in the VP4/VP2 region offers promise in the characterization of rhinovirus strains. 
 
 
 
5.4 SPECIAL FEATURES OF RHINOVIRUS 87 (III, IV) 
 
Human rhinovirus serotype 87 differs from the other rhinoviruses in several ways. 
While the receptors of the other rhinoviruses were characterized some time ago, the 
receptor for HRV87 remains unknown (Uncapher et al., 1991). Analysis of genetic 
relationships of rhinoviruses at the 5’ NCR has revealed the deviant clustering of 
HRV87 (Andeweg et al., 1999). Moreover, in Study III, we showed that in the VP4/VP2 
region HRV87 clustered closer to EV70 than to rhinoviruses. The characterization of 
HRV87 was further continued with more extensive sequence analysis to assess antigenic 
characteristics, acid sensitivity and receptor usage.  
 
After the initial comparison of the VP4/VP2 sequence of HRV87 with the complete 
rhinovirus and enterovirus genomic sequences in GenBank, we noted that the similarity 
of HRV87 was even greater with the partial VP2 sequence of EV68 (Pulli et al., 1995) 
than with EV70. We subsequently sequenced four distinct genomic regions of the 
HRV87 prototype strain and two sublines of the EV68 prototype strain Fermon and 
compared them with the complete genomic sequence of EV70 obtained from GenBank 
(Ryan et al., 1990). Phylogenetic analysis showed that HRV87 clustered into the HEV-
D group, together with EV68 and EV70, at the two capsid coding regions and the 3D 
polymerase coding region. At the 5’ NCR, HRV87 and EV68 clustered into genetic 
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group 2 (Pöyry et al., 1996) with EV70 and HEV-C enteroviruses, including 
polioviruses. The 5’ NCR of HRV87 contained the additional hypervariable region 
typical of enteroviruses, but not present in rhinovirus genomes. The nucleotide sequence 
encoding the VP1 capsid protein has been shown to correlate well with enterovirus 
serotype (Oberste et al., 1999), and based on this, HRV87 and EV68 are clearly 
members of the same serotype. EV70 is a different serotype but belongs to the same 
genetic cluster, HEV-D.  
 
One-way antigenic cross-reactivity was demonstrated between HRV87 and EV68. 
Antisera raised against EV68 effectively neutralized both HRV87 and EV68, while 
antisera to HRV87 had only a slight effect on the infectivity of EV68. Accordingly, 
EV68 is the prime strain of HRV87, since by definition, a prime strain exhibits a 
broader antigenicity than a “prototype” virus; HRV87 should thus be considered a 
prototype strain of this virus pair. Prime strains have previously been described for both 
enterovirus (Pallansch & Roos, 2001) and rhinovirus prototype strains; for example, the 
strain Chase is a prime strain of HRV22 (Schieble et al., 1970). In addition, several 
antigenic variants of HRV17 that fulfil the criteria for being a prime strain, have been 
isolated (Patterson & Hamparian, 1997).  
 
The HEV-D cluster, the smallest of the four genetic clusters of enteroviruses (HEV-A to 
HEV-D), has previously been reported to have only two representatives, EV68 and 
EV70. The prototype strain Fermon of EV68 was isolated from a throat swab of a 10-
month-old female with pneumonia and bronchiolitis (Schieble et al., 1967), but no other 
isolations of the virus are found in the literature. The same holds true for HRV87, now 
shown to belong to the same serotype as EV68. Antibodies to this virus pair appear, 
however, to be rather common among Finnish people, as represented by the plasma pool 
preparation and the few individual sera studied by us. However, nothing is known about 
any clinical disease caused by these viruses. The acid sensitivity makes infection of the 
alimentary tract suspect, and the infection may well occur in the respiratory tract, as is 
typical of rhinoviruses. In contrast to EV68, the clinical syndromes caused by EV70 are 
well known. EV70 is an atypical enterovirus in that its primary replication site is not the 
alimentary tract, but rather the eye. The first acute haemorrhagic conjunctivitis (AHC) 
epidemic reported to be EV70-associated occurred in 1969 in Ghana, and since then, 
two pandemics and smaller outbreaks have been described to comprise approximately 
100 million cases of AHC (reviewed in Alexander & Dimock, 2002). Besides being a 
causative agent of AHC, EV70 has a propensity to infect the central nervous system,   
occasionally causing paralysis or meningoencephalitis (Pallansch & Roos, 2001).   
 
We assessed the capability of a monoclonal antibody to the decay-accelerating factor 
(DAF) to inhibit the infection caused by HRV87, EV68 and EV70, observing that the 
CPE induced by these viruses in HeLa Ohio cells was clearly inhibited by pre-treatment 
of the cells with the antibody. The HRV87 binding has previously been known to be 
dependent on the presence of sialic acids on the cell surface (Uncapher et al., 1991). The 
HeLa cell receptor for EV70 has been demonstrated to be the DAF (Karnauchow et al., 
1996), but the binding of EV70 to the cell surface is also dependent on the presence of 
sialic acids (Utagawa et al., 1982; Alexander & Dimock, 2002), which are not found in 
DAF (Alexander & Dimock, 2002). To date, EV70 is the only human enterovirus 
observed to require cell surface sialic acids for attachment. The DAF, by contrast, has 
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been shown to serve as a cellular attachment protein for a number of enteroviruses, 
including CBV1 (Shafren et al., 1995), CBV3 (Bergelson et al., 1995; Shafren et al., 
1995; Martino et al., 1998), CBV5 (Shafren et al., 1995) and CAV21 (Shafren et al., 
1997; Newcombe et al., 2003), as well as some echoviruses (Bergelson et al., 1994). 
These viruses seem to require accessory molecules in addition to DAF for successful 
infection; for example, both ICAM-1 and DAF are used by CAV21 (Shafren et al., 
1997). Although we showed, that the infection of HeLa Ohio cells by HRV87 and EV68 
is dependent on DAF, as is also the case for EV70, it remains unresolved whether the 
sialic acid moiety involved is shared by these viruses. While the DAF is expressed 
almost ubiquitously in mammalian (Lublin & Atkinson, 1989), a putatively distinct co-
receptor may give rise to different tissue tropism of these viruses. 
 
Our study clearly showed that HRV87 and EV68 belong to the same serotype in the 
HEV-D cluster of enteroviruses - a finding later supported by others (Ishiko et al., 2002; 
Ledford et al., 2004). Initial misidentification of viruses in the family Picornaviridae 
has been noted regularly. Parechoviruses 1 and 2, for example, were originally assigned 
as enterovirus serotypes echovirus 22 and echovirus 23, respectively, but have 
subsequently been shown to represent a genus of their own (Hyypiä et al., 1992).  In 
addition, the virus pairs echovirus 1 and 8, coxsackievirus A11 and A15, and 
coxsackievirus A13 and A18, have been shown to exhibit such strong serological and 
genetic relationships that they are now classified as single serotypes (Oberste et al., 
1999; Stanway et al., 2004). The most striking feature of virus pair HRV87/EV68 is that 
the viruses are acid-sensitive, a feature typical of rhinoviruses. This result conflicts with 
the traditional classification criteria, which state that enteroviruses are acid-resistant. 
This discrepancy has in part led to a proposal by the Picornavirus Study Group of the 
International Committee for the Taxonomy of Viruses (T. Hovi, pers. comm.) that the 
rhinovirus and enterovirus genera be combined to form a single genus with the 
suggested name Enterhinovirus. 
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6 CONCLUSIONS 
 
 
 
1. We developed a rapid and sensitive microwell RT-PCR hybridization assay for the  
detection of rhinoviral RNA in clinical specimens. The specificity of the assay was 
assessed with a complete collection of rhinovirus and enterovirus prototype strains, a 
step not performed by others. Despite the observation that a few rhinovirus 
prototype and field strains go unrecognized in the hybridization step, the assay 
clearly exceeds the sensitivity of virus isolation in a single cell line. The assay is 
especially useful for analysis of large numbers of clinical specimens. 
 
 
2. Rhinovirus infections were shown to be very common in young children, with 
infections occurring already during the very first months of life. By the age of two 
years, 79% of children had experienced a virologically documented rhinovirus 
infection, and 91.3% had rhinovirus-specific antibodies. A close association between 
rhinovirus infection and acute otitis media (AOM) was confirmed by rhinoviruses 
being detected by isolation or RT-PCR in 41% of all AOM episodes studied. 
 
 
3. Genetic relationships between all 102 rhinovirus prototype strains were studied for 
the first time. In the VP4/VP2 genomic region, the strains were shown to cluster into 
the two established species, Human rhinovirus A (HRV-A) and Human rhinovirus B 
(HRV-B), with only one exception, HRV87. HRV-A contained 76 and HRV-B 25 
prototype strains. The clustering of previously sequenced field strains suggests that 
genetic typing of rhinoviruses is possible and may be a useful tool in characterizing 
rhinovirus field strains. 
 
 
4. Rhinovirus serotype 87 was shown both antigenically and genetically to represent 
the same serotype as enterovirus 68, and thus, to belong to the enterovirus species 
HEV-D together with EV70. Based on the prevalence of neutralizing antibodies, the 
virus pair HRV87/EV68 is relatively common among Finnish people. HRV87/EV68 
appears to share the HeLa cell DAF receptor with EV70. In contrast to other 
enteroviruses, HRV87 and EV68 are sensitive to an acidic environment.  
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